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Abstract
Vascular calcification (VC) is an important complication of chronic renal failure (CRF),
and a risk factor for reduced survival. Osteoblast-like cells in the vessel wall derived from 
resident vascular smooth muscle cells (VSMC) are considered central to the pathogenesis 
of VC, which is exacerbated by mineral ion abnormalities inherent in renal 
osteodystrophy (ROD). Nevertheless, its aetiology is incompletely understood, and no 
effective therapies exist. Recendy, CRF has been characterised as a state of Bone 
Morphogenetic Protein 7 (BMP7) deficiency, and animal studies have shown that 
administration of this renal morphogen is efficacious in treating several aspects of renal 
failure, including progressive renal fibrosis and ROD. The hypothesis of this thesis is that 
BMP7 deficiency contributes to the pathogenesis of VC, by facilitating the emergence of 
the osteoblast-like cell, and that exogenous BMP7 administration abrogates it by 
normalising VSMC behaviour.
This hypothesis was tested in atherosclerotic Low Density Lipoprotein Receptor Null 
(ldlf/) mice. Uraemia was superimposed surgically to generate VC. Animals received
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BMP7 or vehicle over 15 weeks. Untreated uraemic animals had increased VC on 
histological and chemical grounds, and demonstrated increased expression of the 
characteristic osteoblast protein osteocalcin was demonstrated in vascular tissues. Both 
changes were reversed by BMP7 administration. Uraemic animals were shown to have an 
adynamic form of ROD, also reversed by BMP7 administration, suggesting that 
normalisation of mineral ion abnormalities may underlie the benefits of BMP7 on VC in 
CRF. In addition, in vitro studies showed that BMP7 can act directly on vascular cells to 
reduce extracellular calcification under conducive conditions. Finally, in an appendix, 
preliminary data is presented showing that expression of LRP5, a protein involved in the 
control of normal bone mineralization, may be increased in Idlr1 animals, suggesting that 
consequences of this genotype may be important to VC pathogenesis in this model.
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Section 1
Overview
Vascular calcification (VC) has recently emerged as an important complication of
chronic renal failure (CRF), with serious consequences for morbidity and mortality in 
patients with end-stage renal disease (ESRD). Current understanding of the aetiology of 
this widespread problem is incomplete, and no effective therapies are available. However, 
several recent studies in animal models have shown striking efficacy of the renal 
morphogen Bone Morphogenetic Protein 7 (BMP7) in treating a number of aspects of 
renal failure and the uraemic syndrome, including acute ischaemic renal injury, 
progressive tubulo-interstitial fibrosis, diabetic nephropathy, lupus nephritis and renal 
osteodystrophy. These results led to the broad hypothesis that BMP7 administration may 
also be beneficial to VC in the context of CRF, and this hypothesis is the subject of this 
thesis.
The rationale underlying these beneficial effects of BMP7 administration is that 
endogenous BMP7 expression in the kidney is decreased soon after renal injury, and that 
the absence of this important growth factor facilitates progressive renal injury mediated
by other factors, such as Transforming Growth Factor-^ (TGF6). Thus CRF has been 
characterised as a state of relative BMP7 deficiency, and in this setting administration of 
exogenous BMP7 serves to promote normal end-organ structure and function by 
restoring the balance between counteracting beneficial and pathological influences.
This paradigm of BMP7 deficiency in CRF may be expanded to explain the aetiology of 
VC, by extension to vascular smooth muscle cells (VSMCs). VSMCs have emerged to 
play a central role in the aetiology of VC, and appear to adopt a phenotype reminiscent 
of osteoblasts through a process of transdifferentiation in this context. Osteoblasts are 
the major anabolic cells of bone, and function to mineralise their extracellular matrix; 
VSMCs that have undergone osteoblastic transformation are able to mineralise their own 
extracellular matrix in an analogous manner, and thereby generate VC. Although the 
effects of BMP7 on VSMCs are not clearly understood, they derive from the same 
mesenchymal precursors as other targets of BMP7, and BMP7 is known to play a role in 
fate-determination and maturation of other cells in this lineage, including osteoblasts. It 
may therefore be hypothesised on the one hand that BMP7 deficiency in CRF could lead 
to structural or functional changes in VSMCs, and in particular facilitate their osteoblastic 
transdifferentiation. Exogenous BMP7 administration in this context would potentially 
restore normal smooth muscle cell function, and by doing so ameliorate or prevent VC. 
On the other hand, it is also possible to hypothesise that BMP7 might worsen VC, since 
it plays a key role in the differentiation and maturation of osteoblasts in normal bone and 
could therefore potentially accelerate the transdifferentiation of VSMCs to a mineralising 
phenotype in the vasculature. Such an outcome would clearly outweigh benefits of 
exogenous BMP7 administration on other aspects of CRF.
18
This thesis aims to explore these opposing hypotheses, and comprises a review of both 
current understanding of VC and the role of BMP7 in health and disease of renal tissues, 
followed by four studies performed to test the hypotheses outlined above. Firstly, two 
studies are described in an animal model of atherosclerosis and arterial calcification, the 
Low-Density Lipoprotein Receptor null {Idlr1) mouse, onto which uraemia was 
superimposed by a surgical procedure. These studies demonstrate through histological, 
chemical and immunohistochemical techniques that VC is induced in uraemic animals, 
and that this process is prevented by BMP7 administration. At the same time, 
abnormalities of bone histology consistent with renal osteodystrophy (ROD) were also 
apparent in these animals, and these changes too were reversed by BMP7. The interplay 
between VC, ROD and abnormalities of mineral metabolism inherent in CRF is 
discussed. Following this is a description of studies performed in an in vitro model of 
VC, the bovine calcifying vascular cell (CVC). These cells are characterised as VSMCs 
expressing an osteoblastic phenotype, and spontaneously calcify their extracellular matrix. 
Again, BMP7 administration ameliorated calcification both under basal conditions and 
also conditions promoting maximal mineralization. The appendix describes an analysis of 
the vascular expression of LRP5, a protein structurally and functionally related to the 
LDL receptor that plays an essential role in normal osteoblast development and 
maturation. The study demonstrates increased expression of LRP5 in the context of the 
Idhr1 genotype, and suggests a mechanistic link between this lesion and the emergence of 
VC. The putative interrelationship between this finding and the observed effects of 
BMP7 is briefly discussed.
The conclusion of the thesis is that the data described support the hypothesis that BMP7 
administration prevents VC in CRF, through direct effects on vascular cells as well as 
indirect effects on bone mineralization, and further that consequences of the Idbr1
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genotype may be important to the pathogenesis of VC and its treatment in this setting. 
More generally, the thesis supports the concept of CRF as a state of relative BMP7 
deficiency, and contributes to the hope that new, effective therapeutic options will be 
developed for the treatment of VC and other aspects of CRF in the future.
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Section 2
Introduction to vascular calcification and the role of Bone 
Morphogenetic Protein 7 in physiology and pathophysiology
22
2.1 The pathophysiology o f vascular calcification
2.1.1 The clinical importance of vascular calcification in chronic renal failure
Registry data from both the USA and Northern Europe have consistently demonstrated
an excess mortality in patients with end-stage renal disease (ESRD) [1-3], despite 
measures to optimise dialysis treatment and pre-dialysis care. Approximately fifty percent 
of all deaths in such patients are attributable to cardiovascular disease [4], and this 
problem remains one of the major outstanding issues in clinical nephrology. In an early 
and influential paper addressing this issue, Lindner et al concluded that accelerated 
atherosclerosis was the major cause of this excess cardiovascular mortality [5]. Given the 
high incidence of established atherosclerotic risk factors characteristic of the metabolic 
syndrome in the chronic renal failure (CRF) population [6], such as hypertension, 
dyslipidaemia, insulin resistance and overt diabetes mellitus, such a conclusion is 
attractive; however subsequent reports have challenged its validity [7-10], and it remains 
to be shown conclusively that excess mortality in this setting is caused by accelerated 
atherosclerosis per se. Other factors have therefore been sought to explain the excess
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cardiovascular mortality in CRF [11], and included among these is vascular calcification 
(VQ [12].
VC is prevalent in the general population and has been viewed until recently as 
characteristic of ‘normal’ aging. Nevertheless, the presence of coronary artery 
calcification has clearly been shown to be predictive of cardiovascular mortality in both 
general and renal populations [13-16], and so VC is likely to have pathological 
significance. In the CRF population, VC is more extensive than in the general 
population on both histological [8] and radiological grounds [15, 17]. One radiological 
study by Goodman et al has clearly shown that VC occurs from a young age in patients 
on dialysis [17], data that is consistent with the extremely high mortality rates seen in 
such patients [11]. This study also showed that the presence of VC correlated strongly 
with time on HD, with increased serum calcium and phosphate ion product and with 
ingestion of increased amounts of calcium-based phosphate binders used in the 
treatment of renal osteodystrophy (ROD) [17]. Such a link between VC and the 
abnormalities of mineral metabolism inherent in ROD has come to be seen as centrally 
important, with large population-based studies independently confirming the association 
between increased serum phosphate concentrations and VC [4] and subsequently 
demonstrating that elevation of both serum phosphate and serum calcium concentrations 
are predictive of increased mortality [18]. Recent data have also demonstrated an 
increased risk of mortality associated with normal serum calcium concentrations in 
patients with ESRD, when values at the upper end of the normal range are compared to 
those at the lower end [14]. Finally, both elevated levels of Parathyroid Hormone (PTH) 
[18] and the use of Vitamin D analogues for the treatment of secondary 
hyperparathyroidism [19] have been linked to VC and mortality. In addition to this data 
focussing on ROD, other studies have also linked VC to diabetes mellitus (DM) [15, 20],
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hypertension [8], and duration of renal disease [8]. Taken together, these data suggest 
that while VC is undoubtedly a product of the uraemic milieu, it may also be in part an 
iatrogenic disease that occurs as a consequence of current therapies aimed at treating 
ROD.
At a histological level, two patterns of VC are described. In the context of severe 
atherosclerosis, calcification is localised to the intimal layer of the vessel wall immediately 
related to the plaque [21], and nearby vessel wall is usually entirely normal. Alternatively, 
calcification may be found throughout the medial layer of the arterial tree, particularly at 
the internal elastic lamina, extending from the proximal aorta to small arteries and even 
arterioles [22]. This second form of VC, sometimes referred to as Monckeberg’s 
sclerosis, is confluent and largely unrelated to intimal atherosclerotic disease, which may 
nevertheless coexist at localised sites. Medial VC of this type is commonly severe enough 
to be readily visible on plain radiography, and the density of this calcification in vascular 
tissues may not be dissimilar to that in adjacent bone (Figure 2.1). Extensive medial 
calcification such as this is particularly characteristic of CRF, although it is also seen in 
relation to the aging process and in DM in the absence of overt nephropathy [22]. It is 
worth noting that in these latter cases, in contrast to CRF, most patients will have normal 
calcium and phosphate homeostasis.
Whether on the one hand these two different histological patterns of VC represent 
different pathological processes, or whether on the other they represent the same 
pathological process acting under different circumstances of vascular injury, has not been 
determined. It is worth noting that the data correlating VC to morbidity and mortality on 
radiographic grounds [13, 16] do not distinguish between the two different histological - 
distributions of VC, but instead estimate total vascular calcium load. Thus,
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Figure 2.1 Plain abdominal radiograph illustrating extensive calcification of the inferior aorta
and iliac arteries in a patient receiving peritoneal dialysis (white arrows). Note that the radiodensity 
of vascular calcification is similar to that of bone in this example. There is also incidental calcification of the 
visceral peritoneum (arrows).
26
the clinical significance of vascular calcification derives from the biophysical alterations it 
imposes on the vessel wall attributable to both patterns. Focal calcification around 
atherosclerotic lesions increases plaque fragility, which in turn makes that part of the 
vessel wall more vulnerable to shear stresses, precipitating acute plaque rupture and 
thrombosis [23]. This is likely to explain the correlation between coronary artery 
calcification and mortality [13], and complications after angioplasty [24] and bypass 
surgery [25]. Medial calcification on the other hand affects cardiovascular morbidity 
through a different mechanism, which may be clinically more significant in CRF. The 
main consequence of the confluent nature of the mineralization in this situation is a 
generalised increase in stiffness of the vessel wall, which is reflected in reduced vascular 
compliance [26-28] and which has a number of detrimental effects on the cardiovascular 
system. Widening of the pulse pressure (PP) occurs, reflecting a small increase in systolic 
blood pressure (SBP) and a more marked fall in diastolic blood pressure (DBP), and this 
is a stimulus for left ventricular hypertrophy, LVH. LVH is in turn an independent risk 
factor for cardiac mortality in the ESRD population, and while undoubtedly 
multifactorial in origin in this patient group (influenced by such factors as chronic 
anaemia, hypertension, fluid overload, iron overload and the direct effects of parathyroid 
hormone on cardiac fibrosis), the striking VC that is often present in this setting is likely 
to play an important role in its aetiology. The fall in diastolic pressure also reduces 
coronary perfusion, which is predominandy a diastolic process. Thirdly, there is 
accelerated propagation of the systolic pulse wave through the arterial tree, and an 
equally accelerated reflection of this wave from the peripheral vascular beds, which 
arrives back at the LV outflow tract earlier in the cardiac cycle. This in turn causes 
turbulent flow to occur at the coronary ostia, which further impairs coronary perfusion 
in diastole [28]. Overall, these changes stimulate the development of LVH and
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exacerbate myocardial ischaemia; it is not surprising, therefore that pulse wave velocity 
(PWV) a measure of arterial stiffening [29], is an independent predictor of all-cause and 
cardiovascular mortality.
Importandy, human studies have demonstrated the association between these vascular 
and cardiac changes consequent on the presence of medial VC and mortality in CRF [26- 
28, 30, 31], and the United States Renal Data System (USRDS) data shows both that 
pulse pressure is widened in the CRF population compared to the general population 
[32], and that this change in pulse pressure is related to mortality in such patients [33]. In 
a recent study by London et al,\ the relative risk of cardiovascular and all cause mortality 
associated with the presence of arterial media VC was 60- and 46-fold higher than in its 
absence respectively [34], emphasising the importance of VC as a cardiovascular risk 
factor.
Thus VC has emerged as an important potential candidate to explain the excess 
cardiovascular mortality of CRF. Investigations into its pathogenesis are clearly 
warranted, with the expectation that clearer understanding of this phenomenon might 
lead to the development of effective therapies that will significantly improve the 
prognosis for patients with renal failure.
2.1.2 Pathophysiological mechanisms of vascular calcification
Despite being observed at least 150 years ago [35], VC has received little scientific 
attention until the last decade or so, when assumptions that it is a passive and dystrophic
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process of little clinical significance have progressively been undermined. A number of 
lines of evidence suggest that VC is in fact an active process with strong parallels to 
normal endochondral bone mineralization [12, 36]. Firstly, clinical and histological 
descriptions have noted structures strongly resembling bone and containing normal bone 
marrow elements within the walls of calcified vessels [37, 38]. Secondly, the particular 
form of calcium phosphate crystal found in vessel walls is hydroxyapatite, the form 
found in bone [39]. Thirdly, matrix vesicles have been described in calcifying 
atherosclerotic plaque and aortic tunica media [40, 41]. These sub-cellular structures are 
the focus of initiation for calcification in normal endochondral bone mineralization, and 
have been shown to be functionally important in mineralization initiated by calcifying 
cells of vascular origin in vitro [42]. Fourthly, immunohistochemistry and in situ 
hybridisation have demonstrated the expression of a variety of characteristic bone-related 
proteins in association with calcified atheromatous plaque. These include collagen I [43], 
the major collagen of bone extracellular matrix, and a number of non-collagenous bone 
matrix proteins, including Bone Morphogenetic Protein 2a (BMP 2a) [39], Osteopontin 
[44-48], osteocalcin [36], matrix Gla-protein (MGP) [46], and alkaline phosphatase [36, 
37, 49]. While the expression of these proteins could be interpreted as a response to 
calcification rather than its driving mechanism, data from a number of cell culture 
models strongly supports the concept that this pattern of gene and protein expression 
reflects the presence in the vessel wall of a cell expressing an osteoblast-like phenotype, 
and that this cell is central to the aetiology of VC. It has been further suggested that the 
expression of key morphogens such as BMP2 may be a critical initiating step in this 
process.
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2.1.2.1 The osteoblast-like cell
Demer’s group [39], and subsequently others [50, 51], have isolated primary vascular
smooth musde cell (VSMC) cultures from explants of medial tissue from both normal 
and diseased aortas which adopt a calcifying phenotype in vitro. These cells express the 
wide array of bone-related proteins mentioned above, and of particular significance is the 
observation that these calcifying VSMCs, termed calcifying vascular cells or CVCs, follow 
the critical sequence and timing of expression of these proteins as it occurs in normal 
mineralising bone [52, 53], albeit over an accelerated time-frame. As cells differentiate 
into mature osteoblasts in bone the ability to proliferate is lost, while at the same time 
synthesis of appropriate matrix components begins, predominantly collagen I. In turn, 
the accumulating matrix signals to the cell to initiate secretion of proteins relating to 
mineralization, firstly alkaline phosphatase and osteopontin, later osteocalcin and MGP. 
The synthesis of an appropriate type of matrix critically influences calcification [54]: 
rapidly calcifying CVCs synthesise a matrix containing high levels of Collagen I and 
Fibronectin, while more slowly mineralising cells synthesise matrix with less Collagen I 
and Fibronectin and more Collagen IV. Importantly, when slowly mineralising CVCs are 
transferred onto matrix synthesised by rapidly mineralising CVCs, their rate of 
mineralising increased to a comparable level as the rapidly mineralising cells. On the 
other hand, other VSMC derived from the same bovine vascular tissue never calcified, 
irrespective of matrix, suggesting that both intrinsic cellular characteristics as well as 
external environment contribute to the propensity of CVCs to calcify. These influences 
appear to be mediated, at least in part, through a5 integtins involved in cell/matrix 
interaction. In addition, CVCs express the transcription factor cbfal/osf2 [55], a factor 
both essential and sufficient for differentiation of the mature osteoblast in bone [56]. 
However, whether the ability to calcify is a characteristic of all VSMCs isn’t clear.
Table 2.1 Factors influencing calcification of vascular smooth muscle cells, 
calcifying vascular cells (CVCs) and pericytes in  vitro
Factors Increasing Calcification Factors Decreasing Calcification
cAMP [55] Autocrine/paracrine PTHrP [64]
Organic phosphate [50, 56] Osteopontin [51]
Inorganic phosphate [57] Collagen IV [62]
Alkaline phosphatase [50]
Corticosteroids [58]
Vitamin D3 [59]
Oestrogens [60]
Oxidised Lipids [57]
TGF-pl [57]
Advanced Glycation Endproducts [61]
Collagen I [62]
? ‘Intracrine’ PTHrP[63]
PTHrP, Parathyroid Hormone related peptide
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CVC clones calcify spontaneously and rapidly throughout their existence in vitro-, in 
contrast other VSMC clones derived from the same vascular explants may never do so 
[57]. This suggests the existence of either two phenotypically different cell lines in the 
original tissue, or that certain VSMCs retain sufficient pluripotentiality to change their 
phenotype. One important characteristic of calcifying clones is their ability to synthesise 
an appropriate matrix: [54] cell lines that express Fibronectin and Collagen I promote 
mineralization, whereas those expressing Collagen IV inhibit it. A number of studies 
have investigated the process of calcification in this cell-line, suggesting it is a cAMP 
mediated mechanism [55], and influenced by a variety of factors, including Transforming 
Growth Factor (3 (TGFB) (Table 2.1) [50, 51, 54, 55, 57-61, 63-65]. While intermittent 
stimulation of CVCs by cAMP causes a nodular pattern of calcification, continuous 
stimulation causes a confluent calcification throughout the cell monolayer, strikingly 
similar to in vivo medial calcification seen in CRF [55].
The combination of these in vivo and in vitro findings suggest that cells normally resident 
in the vessel wall of healthy aortic tissues have the capacity to adopt a calcifying 
phenotype under appropriate conditions, and behave extremely similarly to normal 
osteoblasts. These observations raise the question of the origin of these calcifying cells.
2.1.2.2 The origin of the osteoblast-like cell
T he most likely derivation of the osteoblast-like cell in the vessel wall is that is arises by
transdifferentiation of vascular smooth muscle cells, which are both the major cell type in 
the arterial medial layer, and which also migrate into evolving atherosclerotic plaques.
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Smooth muscle cells and osteoblasts share a common derivation from bone marrow 
mesenchymal precursor cells, and whereas osteoblasts are terminally differentiated cells 
unable to re-enter the cell cycle, smooth muscle cells retain a degree of pluripotentiality 
that enables them to transdifferentiate into an osteoblastic phenotype, at least in vitro [66]. 
In the setting of smooth muscle cells in culture, changes in protein expression that are 
consistent with osteoblastic transdifferentiation may be induced by TGFB [67]. In 
particular, expression of Collagen I, a key component of osteoblastic extracellular matrix, 
is increased, while expression of both Collagen III, which is characteristic of extracellular 
matrix synthesised by VSMCs, and a-Smooth Muscle Actin (aSMA), which is a marker of 
smooth muscle phenotype, are decreased. The precise mechanisms underlying the 
relationship between these two cell lineages are not clearly understood, but available 
evidence suggests that Bone Morphogenetic Protein 7 (BMP7) may play a key role, both 
in defining the two lineages under normal physiological conditions, and also in facilitating 
the transdifferentiation process by its absence under pathological conditions in CRF 
(Figure 2.2). While BMP7 is known to be critical for the commitment of precursor cells 
to the osteoblastic lineage, the factors committing precursors to the VSMC lineage are 
unknown. However, data from animal studies and from cell culture experiments suggest 
that BMP7 may be able to contribute to preservation of smooth muscle phenotype in 
committed cells [67], and prevent the transdifferentiation process, at least when it is 
driven by TGFB [67]. This point is discussed in more detail below, in section 2.2.
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2.1.2.3 Renal osteodystrophy and vascular calcification
A s noted previously, clinical studies have associated the presence of VC in patients with
CRF with a number of parameters characteristic of the presence of ROD, such as 
increased calcium and phosphate ion concentrations [4, 14, 17, 18] and PTH levels [18], 
as well as with the use of agents used in the treatment of ROD such as calcium-based 
phosphate binders [17], and Vitamin D analogues [19]. In addition, in vitro studies have 
clearly shown the strong and direct influence of phosphate on VSMCs and CVCs in both 
initiating and promoting calcification by these cells [50, 68]. It is thus relevant to 
understand the pathogenesis of ROD and why this disease may affect the aetiology of 
vascular calcification.
ROD forms a histologically-defined spectrum of bone disease characterised by secondary 
and tertiary hyperparathyroidism, which ranges from the high-tumover state of Osteitis 
Fibrosa (OF) at one extreme to the low-tumover state of Adynamic Bone Disease 
(ABD) at the other [69, 70]. It is clear from bone histology studies that not all cases fall 
into these polarised categories, but may occupy intermediate positions between them. 
Nevertheless, it is useful to consider the extreme cases when attempting to understand 
the pathological processes involved.
The aetiology of ROD is conventionally understood to involve a complex interaction 
between several factors associated with loss of renal parenchyma and falling Glomerular 
Filtration Rate (GFR) (Figure 2.3a and b). In OF (Figure 2.3 a), reduced synthesis of 
activated Vitamin D (1, 25 dihydroxy-cholecaldferol) leads to a tendency to 
hypocalcaemia due to reduced intestinal absorption; in addition, reduced tubular 
phosphate ion excretion leads to hyperphosphataemia. Hypocalcaemia,
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hyperphosphataemia and Vitamin D deficiency all combine to stimulate an increase in 
Parathyroid Hormone synthesis and secretion, as part of a physiological feedback loop 
that acts to maintain normal extracellular calcium and phosphate concentrations. The 
major consequence of this hyperparathyroidism is increased bone turnover, with 
increased numbers of osteoblasts associated with bone formation rate and osteoid 
accumulation, as well as increased numbers of osteoclasts associated with bone 
resorption. Overall, a net bone resorption of bone occurs due to imbalance in the 
regulation of these processes, tending to increase the concentration of both phosphate 
and calcium ions in the extracellular fluid. However, the persisting limitation on renal 
tubular phosphate excretion contributes to ongoing hyperphosphataemia despite 
hyperparathyroidism, so that even while calcium concentrations may be normal, an 
increased calcium phosphate ion product occurs. The presence of hyperphosphataemia 
represents an important link between high-tumover bone disease and VC, since 
hyperphosphataemia has been shown to be predictive of cardiovascular mortality [4, 18, 
71], and phosphate ions have been shown to be able to initiate a calcifying phenotype in 
VSMCs [50, 68] as well as promoting mineralization by CVCs. In addition, it has been 
speculated that high levels of parathyroid hormone itself may act to promote VC [71].
In contrast to OF, ABD is characterised by low numbers of osteoblasts, with normal or 
reduced numbers of osteoclasts. Mineralization proceeds at a normal rate, and osteoid 
thickness may be normal or decreased [72, 73], but overall bone turnover is low. It is 
interesting to note that such a low turnover state has been observed in a murine model of 
CKD treated with Vitamin D in the context of normal calcium, phosphate and PTH 
levels, at a stage when GFR is approximately 60 % normal [74]. This indicates that there 
may be a decrease in bone anabolism early in the course of CKD, before abnormal 
phosphate or PTH levels are demonstrable. Since BMP7 is known to be an anabolic
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Figure 2.3 Classical paradigm o f the aetiology o f renal osteodystrophy (ROD). A, In high
turnover ROD, loss of functional renal tissue reduces activated Vitamin D (1,25D) synthesis (1), causing 
reduced intestinal Ca2+ absorption and hypocalcaemia (2). Reduced renal P 0 4 excretion leads to 
hyperphosphataemia (3). Hypocalcaemia, hyperphosphataemia and 1,25 D deficiency combine to stimulate 
Parathyroid Hormone (PTH) synthesis (secondary hyperparathyroidism, 2HPT) (4), causing increased bone 
turnover (5) and peritrabecular fibrosis (Osteitis Fibrosa, OF). N et bone resorption increases extracellular 
P 0 4 and Ca2+ concentrations (6); persisting limitation of renal P 0 4 excretion contributes to ongoing 
hyperphosphataemia despite hyperparathyroidism. B, Adynamic bone disease often derived from aluminium 
(Al3+) toxicity (1). More recently it is a consequence of over-treatment of 2HPT with both 1,25D analogues 
(la) (2), and dietary binders (PB) used reduce P 0 4 absorption (3). Both suppress PTH synthesis (4) and 
reduce bone turnover (5). Paradoxically 1,25D analogues promote intestinal Ca2+ and P 0 4 absorption (6), 
particularly when Ca2+-containing binders are used. In addition, reduced bone turnover reduces capacity to 
buffer extracellular Ca2+ and P 0 4 (7), causing persistent abnormalities of mineral metabolism.
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factor in healthy bone and since the renal expression of this protein is reduced early after 
renal injury [75, 76], it is attractive to hypothesise that reduced BMP7 expression is an 
important mechanistic step in the initiation of ABD, which may therefore both precede 
and initiate OF. This hypothesis if confirmed would lend further support to the concept 
that CKD is a state of BMP7 deficiency, a point discussed further below, in section2.2.3.
The link between VC and ABD is perhaps not so obvious, but nevertheless may be 
extremely important Historically, ABD was either not seen or was seen only rarely in 
ESRD, and often in relation to aluminium toxicity. However despite reduction in 
exposure to aluminium in the CRF patient population, its prevalence has steadily 
increased. More recently it is considered to be at least in part a consequence of successful 
management of OF [72] (Figure 2.3b), in which focus of treatment of this condition is to 
normalise serum phosphate concentrations and suppress PTH secretion using dietary 
phosphate binders and vitamin D analogues. The combination of these therapies 
removes a number of important major stimuli to bone turnover, and ABD may result 
[72]. As a direct result of this reduction in bone turnover, there is also a reduction in an 
important physiological compartment, the Rapidly Diffusible Calcium and Phosphate ion 
pool (RDIP), and this change is likely to underpin the link between ABD and VC. The 
RDIP exists at the bone surfaces in association with the resorbing and mineralising 
fronts, and although it does not have any strict anatomical definition, its sfre varies in 
proportion to the amount of bone turnover [77]. In addition to accommodating the ions 
involved in bone turnover, one of the key functions of the RDIP is that it serves to 
buffer extracellular calcium and phosphate ion concentrations over short time-frames, 
for instance in the immediate post-prandial period. This allows the body to maintain 
tightly controlled levels of these ions over shorter periods of time than can be achieved 
via buffering by bone mineral itself or by adjustments in renal tubular ion fluxes. Thus,
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while patients with ABD may have satisfactory ion levels for most of the time, they are 
prone to peaks of ion concentrations after meals, and since pulses of phosphate have 
been shown to be able to induce a mineralising phenotype in VSMCs in vitro [68], this 
may have important consequences for the aetiology of VC. In support of this concept, a 
recent study has shown a clear association between the presence of VC detected 
radiologically and ABD diagnosed on bone biopsy in the same patients [78].
It can therefore be seen that ROD of whichever type will contribute to disturbances of 
calcium and phosphate homeostasis that are likely to contribute to the pathogenesis and 
progression of VC, and by doing so contribute to the excess cardiovascular mortality of 
CRF.
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2.2 Bone Morphogenetic Protein 7
T he role of BMP7 in the aetiology of aspects of the uraemic syndrome, and its
emergence as a potentially useful therapeutic agent in this setting, is central to the current 
thesis. It is thus worth taking time to discuss the biology of this protein in health and 
disease in order to understand its role in pathophysiology and treatment of vascular 
calcification in CRF.
2.2.1 Structure and function
T he Bone Morphogenetic Proteins (BMPs) are a large subgroup of the TGFB super­
family of cytokines, comprising at least 30 members throughout the animal kingdom, 
which are highly conserved throughout evolution [79, 80]. They are named for their 
osteo-inductive properties, since they are able to recapitulate formation of endochondral
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bone as well as haematopoetic marrow elements at extra-skeletal sites [81]. However, 
their nomenclature is an accident of the circumstances of their discovery, and BMPs are 
clearly not fiinctionally limited to bone development Indeed, they are widely expressed 
throughout embryonic development, and play an essential role in organogenesis and axial 
patterning in addition to skeletal development, influencing processes as diverse as 
proliferation, differentiation and apoptosis in doing so [79].
BMPs are synthesised as large precursor proteins which form dimers and are 
subsequently cleaved at a consensus Arg-X-X-Arg sequence to yield mature carboxy- 
terminal dimers. This process occurs before secretion. X-ray crystallography has 
demonstrated that BMP monomers are characterised by an invariant motif, a cystine 
knot comprising six cysteine residues; in addition, virtually all BMP family members have 
a seventh cysteine residue, involved in disulphide bonding in the dimerization process 
(79],
Interactions between secreted dimers and their receptors are complex, but follow a 
general paradigm of all TGFB superfamily members [79] (Figure 2.4). Ligands bind to 
one of a number of type II transmembrane serine-threonine kinase receptors, which then 
forms a heterodimer with one of a number of type I receptors, also a transmembrane 
serine-threonine kinase. The type I receptor is then phosphorylated and activated by the 
type II receptor, and initiates further signal transduction via the Smad pathway, in 
common with TGFB super-family signalling as a whole, leading to appropriate 
modification of gene expression [79]. Each protein may interact with a number of Type I 
and Type II receptors, leading to considerable promiscuity in these ligand/receptor 
relationships. This allows an individual ligand to transduce several effects
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Figure 2.4 Transforming Growth Factor P superfamily signal transduction. Extracellular ligand
binds to a type I receptor, which forms a heterodimer with a type II receptor (a). R-Smads (Smads 1,2,3,5 or 
8) interact with the cytosolic tail of the type II receptor, becoming phosphorylated and active (b). Activated 
R-Smads combine with Co-Smad (Smad 4) (c), and translocate to the nucleus, where the combine with 
Nuclear Binding Factors (NBF), bind to DNA and regulate gene expression (d). Inhibitory Smads (I-Smad, 
Smads 6 and 7) bind to type II receptors and competitively inhibit phosphorylation of R-Smads (e).
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under different circumstances, depending on its specific environment and on the 
maturity of cells on which it is acting. For example, BMP4 has been implicated in axial 
patterning, cell differentiation and apoptosis in neural tissues [79]. *
In addition, the Smad signalling cascade comprises both activating and inhibiting 
components, and individual cytokines may activate either or both, depending largely on 
the particular receptor heterodimer combination through which they are signalling. Since 
a variety of receptor monomers may be expressed by a single cell, both activating and 
inhibitory influences may act within a single cell at the same time. This allows the 
possibility of auto-regulation of some ligand effects, as well as the potential for 
modifying interactions between individual ligands in the TGFB superfamily. For example, 
as discussed below, BMP7 and TGFB itself have been shown to be mutually antagonistic 
in their effects on VSMCs, since BMP7 is able to up-regulate Smad6 which in turn 
inhibits signalling through TGFB driven Smad pathways [67].
Thus the effect of a given ligand depends extensively on context, and cannot be 
predicted a priori. As will be made clear below, the role of BMP7 on vascular smooth 
muscle cells and bone marrow osteoblasts in the uraemic milieu is particularly important 
to the pathogenesis and potential treatment of VC.
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2.2.2 Role in embryonic development and post-partum health
Bone Morphogenetic Protein7 (BMP7), also know as Osteogenic Protein-1 (OP-1), is
widely expressed in a number of embryonic tissues [82], and plays an important role in 
skeleton, eye, kidney [83-86] and cardiovascular system [87, 88] development. In the 
kidney, BMP7 primarily coordinates the interaction between the condensing 
mesenchyme of the emerging metanephros and the branching morphogenesis of the 
ureteric bud [83, 84], while in the skeleton BMP7 plays a role in committing 
mesenchymal stem cells to the osteoblastic lineage, thus facilitating bone mineralization. 
Expression of BMP7 in the eye is implicated in the coordinated development of mature 
structures. Cardiac expression of BMP7 is widespread in the developing heart throughout 
embryonic development.
The relative importance of these roles of BMP7 is illustrated by studies of genetically 
mutant animals. The essential nature of BMP7 expression in renal development and the 
inherent redundancy of BMP signalling is clear from the phenotype of the bmpT1' mouse, 
which is characterised by markedly reduced nephron mass at birth, and perinatal death 
from uraemia [83]. While failure of eye development also occurs in this genetic setting, 
skeletal abnormalities in the bmpT1' mouse are relatively minor, and no cardiovascular 
abnormalities are apparent at time of death. Nevertheless, the importance of BMP7 
expression to cardiovascular development is illustrated by the phenotype of two double 
genetic mutants. In bmp51/  bmpT1' mice [87] cardiac development does not progress, 
with failure of chamber septation and endocardial cushion formation being fatal at about 
10.5 days post conception (dpc). In bmpS1'Ibm fl'1' mice [88], defects of chamber 
septation together with delay in formation of outflow-tract cushion formation and 
consequent defects in valve morphogenesis are lethal at 10.5 to 15.5 dpc. Due to the
lethality of these lesions, the influence of BMP7 on cardiovascular development in later 
life is not currently defined.
In mature animals, BMP7 expression is almost exclusively confined to renal collecting 
tubules, with expression also documented in glomerular podocytes as well as renal artery 
adventitia [75]. The role of BMP7 in the kidney appears to be to preserve the 
differentiated phenotype of glomerular and tubulo-interstitial cell types, by autocrine and 
paracrine mechanisms [89]. In addition, the ongoing importance of BMP7 in osteoblast 
development suggests a hormonal role for renal BMP7, since no expression is 
documented in skeletal tissues in the adult However, no role is clearly defined for BMP7 
in the adult cardiovascular system at present This issue is discussed further in section 
2.2.4 below.
2.2.3 Role in the aetiology and therapy of chronic renal failure and uraemic 
syndrome
Parallels have been drawn between the processes involved in embryonic development of
the kidney and those involved in renal healing after injury. This view is undoubtedly 
overly simplistic, since some degree of progressive fibrosis and anatomical destruction is 
the hallmark of most renal injury, rather than a process of complete recovery. 
Nevertheless, the specificity of BMP7 to embryonic renal development led to the 
hypothesis that BMP7 therapy might improve renal recovery and healing after injury, by 
supporting a more complete embryological program of gene expression. This concept is 
supported by observations in rodent models of DM and acute ischaemic renal injury that
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tubular BMP7 expression is reduced early in the disease process following the initiating 
injury [75, 76], which characterise uraemia as a state of BMP7 deficiency in these settings. 
As a result, the hypothesis that BMP7 therapy may be beneficial in the healing of renal 
injury has been tested in several animal models.
Initial experiments looked at a model of ischaemic nephropathy, and showed that 
animals receiving BMP7 therapy had less marked deterioration in renal function as well 
as faster recovery following injury than control animals [90].
Following this, an important study investigated the effect of BMP7 on tubulo-interstitial 
fibrosis (TIF) [91]. TIF is an important entity since it is a final common pathological 
pathway of virtually all renal diseases. This study used the Unilateral Ureteric Obstruction 
(UUO) model of progressive TIF, in which angiotensin II-stimulated TGF3 expression 
causes progressive interstitial fibrosis following transient surgical ureteric obstruction. 
BMP7 administered for the duration of the obstruction preserved renal function, 
prevented tubular atrophy and markedly diminished the activation of tubulo-interstitial 
inflammation and fibrosis. In addition to demonstrating the efficacy of BMP7 in the 
therapy of a common pathological condition in kidneys, and thereby supporting the 
general concept of chronic renal disease as a condition of BMP7 deficiency, this study 
also emphasises that BMP7 signalling has the potential to antagonise processes mediated 
by TGFB; this in turn has parallels with the interaction between these two cytokines in 
VSMCs, as described above [67].
Subsequently, studies have looked at the effects of BMP7 in models of diabetic 
nephropathy [92] (in which TIF undoubtedly plays a critical pathological role), and lupus 
nephritis, with similarly beneficial effects being seen [93]. In addition, studies particularly
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relevant to this thesis have examined the effect of BMP7 in renal osteodystrophy [94, 
95]. As discussed above, ROD comprises a spectrum of disease entities, ranging from the 
high bone-tumover state of Osteitis Fibrosa (OF) at one extreme, to low turnover 
Adynamic Bone Disease (ABD) at the other. The abnormalities of osteoblast function 
implicit in these disease states together with the role of BMP7 in normal osteoblast 
development suggest that the down-regulation of renal BMP7 expression seen in renal 
injury [75] may be an important contributor to the aetiology of ROD, and that BMP7 
therapy may therefore be beneficial in this context This has proved to be the case in a 
study of high turnover ROD [94], where uraemic mice treated with BMP7 had reduced 
bone resorption, reduced fibrosis and normalised osteoblast characteristics compared to 
untreated controls. In a second study of adynamic bone disease in a similar model BMP7 
therapy again normalised osteoblastic function and improved bone turnover [95]. As 
noted above, there is an increasing amount of clinical data to link biochemical 
consequences of ROD with the aetiology of VC, and this in turn suggests the hypothesis 
that BMP7 may be beneficial in the treatment of this important component of the 
uraemic syndrome.
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2.2.4 Role in cardiovascular biology and potential influence on vascular 
calcification
As noted in section 2.2.2, BMP7 is expressed in the cardiovascular system during
embryonic development [82], and comparison of mice genetically null for BMP7 alone 
[83-86] or BMP7 in conjunction with either BMP6 or BMP5 [87, 88] shows that this 
protein plays an important but not essential role in early embryonic cardiac development 
Unfortunately, the early lethality of these double null animals limits their usefulness in 
understanding the role of BMP7 at later stages of cardiac development, and its role in 
adult cardiovascular biology is not well understood. However, investigations using 
different genetic techniques offer some support for the concept that BMP signalling is 
important in later cardiac development and function [96]. Cre/lox technology allows 
tissue-specific gene deletion limited both spatially and temporally. Studies using this 
technique involving cardiac-limited expression of the Type II BMP receptor ALIO in 
mice have demonstrated the importance of the integrity of BMP signalling pathways in 
several aspects of mid-gestational cardiac development, including cardiomyocyte survival, 
formation of the interventricular septum and the development of the atrioventricular 
cushion [96]. In addition, other studies have used the over-expression of the BMP 
antagonist Noggin to investigate similar pathways in chicks [96]. However, none of these 
investigations have assessed the role of BMP signalling in cardiovascular tissues beyond 
the embryological environment, nor do they address its role in any peripheral vasculature.
Nevertheless, recent studies in humans have linked BMP signalling to normal arterial 
structure and function in the pulmonary circulation. BMPR2 is a type II TGFB 
superfamily receptor specific to BMP signalling, and deletions in the gene for this 
receptor have been linked to Primary Pulmonary Hypertension (PPH) in a large
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proportion of both familial and sporadic cases [97-99]. This condition is characterised by 
hypertrophy of the medial layer of the pulmonary arterial tree due to an imbalance 
between proliferation and apoptosis of pulmonary arterial smooth muscle cells [99,100], 
which in turn leads to increased pulmonary artery pressure, and ultimately to right 
ventricular failure and death. The genetic lesions of BMPR2 are generally predicted to 
lead to truncated non-functioning proteins, a fact which suggests that BMP signalling is 
required for normal control of smooth muscle cell development and function, at least in 
the pulmonary circulation. It is important to note that there is currently no evidence to 
suggest which ligand of the BMPR2 is predominantly affected in this setting, and it is 
also important to note that patients with PPH have no defined pathological phenotype of 
the systemic circulation [96].
Nevertheless, a number of further lines of evidence from in vitro and in vivo studies 
support the hypothesis that BMP7 signalling may have specific importance in normal 
VSMC biology, in the aetiology of vascular calcification and in its treatment First, in 
primary cultures of VSMCs, cells can be induced to calcify under the influence of TGFB, 
as noted previously [67], this effect is accompanied by a shift in gene expression by these 
cells consistent with transdifferentiation into an osteoblastic phenotype. In this setting, 
BMP7 is able to reverse these effects of TGFB and re-establish gene expression 
consistent with the normal VSMC phenotype by increasing expression of the inhibitory 
Smad, Smad6 [67], which is capable of directly inhibiting TGFB signalling through the 
stimulatory Smads 2 and 3. The concept that BMP7 signalling through Smad 6 is 
important in the maintenance of normal VSMC phenotype and the prevention of VC in 
vivo is supported by the observation that the smadS1 mouse is characterised by 
spontaneous aortic calcification in the postnatal period [101]. The relevance of this 
putative effect of BMP-7 in sustaining VSMC phenotype is additionally supported by
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data from a study described above investigating the effect of BMP7 treatment in acute 
ischaemic nephropathy [90], which shows that aSMA expression was induced in 
peritubular blood vessels in the kidneys of animals treated with BMP7 when compared to 
controls.
Taken together, these lines of evidence suggest that BMP signalling in general and BMP7 
signalling in particular have important roles to play in normal cardiac development and 
vascular smooth muscle physiology. Furthermore, disruption of these pathways leads to 
lethal abnormalities of cardiac development in utero, and to significant pathology in the 
adult human. In addition, evidence exists to link BMP7 signalling with the prevention of 
vascular calcification in cellular and animal models. Thus, the occurrence in uraemia of 
both down regulation of BMP7 expression on the one hand together with the presence 
of vascular calcification and high cardiovascular mortality on the other, suggests that 
BMP7 may be an important factor in the body’s defence against VC in health.
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2.3 H y p o th eses
T he hypotheses to be tested in the following studies derive from the data outlined in the 
previous sections, and are as follows:
• that administration of exogenous BMP7 will reduce or prevent the 
development of vascular calcification in the context of chronic kidney 
disease.
• that administration of exogenous BMP7 will improve pathological
changes in bone structure and function in the context of chronic kidney 
disease, in parallel with benefits to vascular calcification.
•  that administration of exogenous BMP7 will prevent pathological
transdifferentiation of vascular smooth muscle cells towards an
osteoblastic phenotype, and directly act to reduce their tendency to
mineralise their extracellular matrix.
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2.4 Sum m ary
In  summary, it has emerged that BMP7 is a critical renal factor both in embryological
development and in maintenance of structural integrity in the adult, that expression of 
this factor is down-regulated in response to renal injury, and that BMP7 has beneficial 
effects when given as therapy in models of several common renal diseases, as well as 
some extra-renal complications of uraemia. The direct effects of BMP7 on smooth 
muscle cells of vascular origin as well as its benefits on the pathophysiology of renal 
osteodystrophy suggest that BMP7 may also have beneficial effects on vascular 
calcification, since the aetiology of vascular calcification in turn depends on abnormalities 
of vascular smooth muscle cell biology that may be promoted by a number of 
pathophysiological components of renal osteodystrophy. If this turns out to be the case, 
it is likely to have important consequences for the morbidity and mortality associated 
with chronic renal failure, since vascular calcification has emerged as an important risk 
factor for excess death in this setting.
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Section 3
The effects of exogenous Bone Morphogenetic Protein 7 on 
vascular calcification in a murine model of chronic renal 
failure and atherosclerosis
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3.1 Aims
As outlined above in section 2, the aetiology of VC is not clearly understood, whether as
a component of the uraemic syndrome or in other clinical contexts. In part, this relates 
to a lack of a suitable animal model. The study described in this section aimed to 
establish such a model, building on the particular association between VC and both 
atherosclerosis and uraemia by superimposing chronic kidney disease on an established 
murine model of atherosclerosis. In addition, the relationship between VC and renal 
failure was investigated by assessing the effect of exogenous BMP7 on VC in this model, 
since evidence supports the concept of CKD as a state of BMP7 deficiency, which can in 
turn be hypothesised to increase the propensity of vascular smooth muscle cells to adopt 
a calcifying, osteoblastic phenotype in the vasculature. Thus, the study has three main 
aims:
• to characterise VC in the context of CKD in a murine model of 
atherosclerosis, using histological assessment
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to identify the presence of cells expressing an osteoblastic phenotype in 
the pathogenesis of VC in this model, by analysing expression of 
osteocalcin in vascular tissues.
to assess the influence of BMP7 on both these factors.
3.2 Introduction
3.2.1. The animal model
T he Low-Density Lipoprotein Receptor null (Idlr1)  mouse in a C57/B16 background
was selected as a suitable model for this study, as animals of this genotype have been 
documented to develop VC spontaneously in the context of atherosclerosis when fed a 
high fat, high cholesterol ‘Westem’-style diet [102].
Vascular calcification is generally difficult to model in laboratory animals. Most rodents, 
which are the most convenient animals to work with experimentally, are resistant to this 
disease process, and unlike humans do not commonly develop spontaneous VC even in 
extreme old age. However, in a comparison of several in-bred mouse strains commonly 
used experimentally, the C57/B16 mouse developed age-related VC the most commonly, 
with an incidence of about 25% [103].
While models of VC exist that use pharmacological manipulation to induce VC, for 
example with low-dose Warfarin regimes [104, 105] or high doses of Vitamin D [106,
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107], such approaches were not felt to be attractive for the current study since they do 
not translate easily to human settings, where no consistent data exist linking these 
pharmacological treatments to VC [12]. While Warfarin use has been associated with 
some cases of the rare disease caldphylaxis (or calcific uraemic arteriolopathy) [108], in 
which patients with end-stage renal failure develop extensive medial-layer calcification in 
small calibre arterial vessels, this is not a ubiquitous finding and it remains to be shown 
that this is a truly causative relationship. In addition, no current human data has linked 
Warfarin use to calcification of larger vessels or in other settings. Given the widespread 
use of Warfarin in the clinical arena, there is unlikely to be any large uncharacterised pro- 
calcific effect of Warfarin yet to be discovered in humans. Vitamin D on the other hand 
has been related to VC in humans in clinical studies [19, 109], although, paradoxically, 
low Vitamin D levels have been correlated with the presence of coronary artery 
calcification [110, 111]. In addition, in vitro studies have shown that Vitamin D is able to 
up-regulate Matrix Gla protein (MGP) expression by rat vascular smooth muscle cells, a 
change which is likely to reduce the tendency of such cells to calcify their extracellular 
environment, and thus potentially reduce VC in rodents [107], Further, it was felt that 
any such pharmacological model of VC would introduce an additional potential 
confounding factor into the study, since the possibility would exist for pharmacological 
interaction between agents used to set up the model on the one hand, and the BMP7 
used in the treatment arm of the study on the other.
In addition to developing spontaneous VC, the Idlr1 model is attractive since is 
genetically homologous to Familial Hypercholesterolemia in humans, and the 
atherosclerotic phenotype can be accentuated by feeding the animals a simulation of a 
‘westernized’ human diet [102]. These animals also exhibit persistent hyperglycaemia 
when fed this atherogenic diet, evidenced by mild elevations of serum glucose
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concentrations. This combination of atherosclerosis, glucose intolerance, dyslipidaemia 
and uraemia in one model therefore has the attraction of reflecting several aspects of the 
complex clinical milieu found in patients with renal failure in the context of type II 
diabetes mellitus, one of the commonest causes of CKD in the clinical setting, and one 
that continues to increase its prevalence.
3.2.2. The model of chronic renal failure
Several models of uraemia have been developed in rodents, variously using surgical,
immunological, genetic or metabolic strategies. We decided to impose uraemia by a 
surgical technique using destructive electrocautery of one kidney followed by 
contralateral nephrectomy two weeks later, to give a decrease in renal function analogous 
to the 5/6 nephrectomy model in rats. This model is technically feasible in mice, and has 
been established to give reproducible amounts of renal injury [112, 113]. One advantage 
of this model, which has previously been used in studies of BMP7 and renal 
osteodystrophy discussed above [94], is that the permanent loss of nephron mass gives a 
fixed reduction in renal function that is not amenable to recovery under the influence of 
the BMP7 treatment, ensuring that any effects of therapy seen on VC are independent of 
changes in glomerular filtration rate. On the other hand, the studies described in section
2.2.3 above indicate that using other uraemic strategies to investigate VC might be 
confounded by the possible beneficial effects of BMP7 therapy on the underlying renal 
lesion itself, through modification of progressive fibrosis inherent in their aetiology.
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3.2.3 Assessment of calcification
There is currently no established gold standard technique for analysing calcification
histologically. We had initially planned to use one of two techniques. Firstly, 
histomorphometry is a well-established technique used to analyse bone mineralization in 
health and disease [114,115], but can be laborious to perform where many small areas of 
calcification need to be defined and analysed, and as will become clear, the punctate 
nature of calcification seen in the vascular tissues in this study made it impractical to use. 
Secondly, a method of calcium quantification based on the elution Alizarin Red-S from 
appropriately stained tissues has been successfully used in an osteoblast cell culture 
system [116], but we were unable to successfully transfer this technique to whole tissue 
preparations. We therefore developed our own scoring system based objectively on the 
presence or absence of calcification, described below.
3.2.4 Assessment of osteoblastic cells in vascular tissues
T o  assess the role of cells expressing an osteoblastic phenotype, we decided to analyse
osteocalcin (OQ expression by tissue immunohistochemistry. OC is a gamma- 
glycosylated (Gla-) protein expressed in normal endochondral bone mineralization, and 
regarded as pathognomonic of mature osteoblastic function and phenotype [119,151]. If 
the hypothesis that transdifferentiation of vascular smooth muscle cells to an osteoblastic
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phenotype were correct, we would expect to find localised OC expression by cells in 
close association with areas of calcification, but not in normal non-calcifying tissues.
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3.3 Methods
3.3.1 Animals and experimental procedures
Animals and diets. All experimental protocols involving animals were
approved by the Washington University Animal Care committee 
(http://medidne.wustl.edu/~acu). Idlf1 mice in a C57B1/6 background were a gift from 
Dr C Semenkovich (Division of Atherosderosis Nutrition and Lipid Research, 
Washington University School of Medicine, St Louis). Animals were allocated to 
experimental groups as shown in figure 3.1. Mice were weaned at three weeks to a 
standard laboratory chow diet. At 10 weeks, animals dther continued chow or started a 
high cholesterol (0.15%) diet containing 42% calories as fat (Tat* ; Harlan Teklad, 
Madison WI, Product No.TD88137) [102]. Animals had access to water ad libitum.
Surgical Procedures. We used a two-step surgical procedure to create
animals with renal impairment [112] (Figure 3.2). In the first procedure, a 2 cm flank 
incision was made and the tight kidney mobilised. Perirenal fat and the adrenal gland
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Idlr v" Mice weaned to Chow
3 weeks
Sacrifice
28 weeks
Vehicle 
13 weeks
Vehicle 
13 weeks
BMP-7 
13 weeks
BMP-7 
13 weeks
Chow Diet
10 weeks
Sham Surgery 
10-12 weeks
Sham Surgery 
10-12 weeks
High Fat Diet 
10 weeks
Uraemic
Surgery
10-12 weeks
Uraemic
Surgery
10-12 weeks
Figure 3.1 Study d esign . Animals were sequentially entered into experimental groups on the basis
o f  diet, uraemic surgery and treatment. Experimental diets were commenced at the same time as the firsl 
uraemic surgery at 10 weeks. Second uraemic surgery was performed at 12 weeks. Experimental treatments 
were started one week after this, to allow animals to adequately recover from the surgical process. See texi 
for full description.
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were separated form the kidney by blunt dissection and the capsule of the kidney 
stripped. The entire renal cortex was cauterised except a 2 mm area around the hilum. 
The kidney was returned to the renal fossa, and subcutaneous tissues repaired with a 
single layer of interrupted sutures. The skin was closed with surgical clips that were 
removed at 7-10 days post-operatively. After a two week recovery period, left 
nephrectomy was performed in a second procedure. The kidney was exposed as before, 
the adrenal gland identified and separated from the kidney by blunt dissection, and the 
renal hilum ligated. After excision of the kidney, the wound was closed as before. 
Control animals received sham operations, involving mobilisation of the kidneys only. 
Animals were allowed to recover for a further week following this second procedure. 
Intraperitoneal anaesthesia (xylazine 13mg/kg and ketamine 87mg/kg) was used for all 
procedures, including animal sacrifice. At sacrifice, the heart and aorta were dissected en 
bloc, to the iliac arteries. For histological analysis, heart and aorta to the arch were 
separated from more distal aorta, and for chemical analysis, the aorta was separated from 
the heart at the level of the aortic valves, then further processed in its entirety.
Blood tests. Saphenous vein blood samples were taken one week
following the second surgery, prior to initiation of therapy, and further samples were 
drawn by right ventricular puncture at the time of sacrifice. Serum was separated from all 
blood samples on the day of blood draw, stored at -80 °C and assayed variously for 
blood urea nitrogen (BUN), cholesterol and glucose by standard laboratory methods.
Treatment groups. This study was structured in two parts. Firsdy, animals
were entered into a protocol to assess vascular calcification in the context of CRF in Idlf1' 
mice fed the high cholesterol diet. Animals in certain groups of this protocol received
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Figure 3.2 Surgical approach. The kidney is mobilized through a 2 cm flank incision, perirenal fat
and the adrenal gland are separated from the kidney by blunt dissection, and the adrenal gland preserved. 
The capsule o f  the kidney is stripped, and the entire renal cortex cauterized, except a 2 mm area around the 
hilum, using an electrocautery probe as shown.
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BMP7 treatment in addition. Blood samples of these animals were used to characterise 
various biochemical parameters in different treatment groups, and aortic tissues were 
assessed histologically for atherosclerosis and vascular calcification. To avoid unnecessary 
animal sacrifice, no chow-fed animals were treated with BMP7, as they were not 
expected to develop significant VC. Immunohistochemistry for osteocalcin was then 
performed on these same tissues. Secondly, in order to confirm aspects of the findings 
concerning osteocalcin expression, a small number of additional animals were given the 
various dietary options without surgery or BMP7 treatment for a shorter period of time, 
and at sacrifice various organs were removed for RNA extraction. Osteocalcin 
expression in these tissues was then assessed by Reverse Transcription PCR.
We allocated animals to six groups: Chow fed animals receiving either sham (‘Chow 
Sham*, Group 1) or uraemic (‘Chow Sham’, Group 2) surgery; high cholesterol-fed 
animals receiving sham (Tat Sham’ Groups 3 and 5) or uraemic (Tat CRF’, Groups 4 
and 6) surgery, and each of these groups received either intraperitoneal BMP7 (Curis Inc, 
Cambridge MA) lOpg/kg in 100 pi vehicle (20mM acetate, 5% mannitol at pH 4.5) once 
weekly (Groups 5 and 6), or 100 pi vehicle alone Groups 3 and 4). This dose was selected 
by extrapolation from previous studies involving rats after discussion within the 
laboratory and with the manufacturers. This treatment began on the day after post- 
surgical phlebotomy.
3.3.2 Tissue processing and analysis
Tissue preparation. For histological analysis, we fixed resected specimens 
in formalin, and then divided as follows: the heart and proximal aorta up to and including
66
the arch were separated from the descending aorta, and bisected sagittally through the 
aortic outflow tract 5 pm thick slices were stained with Alizarin Red and Von Kossa. 
Samples were stored at -  80 °C until assayed. For RNA extraction, we flash-froze 
resected tissues in dry ice/ethanol slurry, and stored at - 80 °C until processed.
Calcification scon. In the absence of an accepted histological method of
VC quantification, we developed the following. For each animal, we scored each of three 
slides stained with Alizarin Red for the presence or absence of calcification in two areas, 
the Intimal and Medial compartments of the proximal aortic sections. We derived a Total 
Vascular score by combining the individual compartment scores for each animal. To 
maximize objectivity in this scoring system, no attempt was made to grade the degree of 
calcification; the system is thus more sensitive in differentiating between no calcification 
and some calcification than it is at differentiating between various degrees of calcification 
where present The scoring system was developed by the author, and one independent 
investigator (RJ Lund) scored all sections in a blinded fashion. Correlation between these 
two scorers was 0.9. Where differences arose, an arithmetic mean was taken.
Immunohistochemistry. Sections were deparaffinised in xylene, rehydrated 
in graded ethanols, incubated in 3% Hydrogen Peroxide to block endogenous peroxidase 
activity and in a solution of casein in PBS (‘Background SNIPER’, Biocare Medical, 
Walnut Creek CA). For OC, antigen retrieval with 5 minute incubation in citrate buffer 
(T)ecloaker’ Biocare Medical, Walnut Creek CA) at 100 °C was performed. Tissue slides 
were incubated with polyclonal antibodies raised against mouse OC in goats (Biogenesis 
Inc, Brentwood NH) diluted 1: 200 (in 2% BSA and 0.04% sodium azide in PBS as per 
manufacturer’s instructions) overnight; then developed with a biotin-streptavidin- 
horseradish peroxidase system (all reagents, Biocare Medical, Walnut Creek CA) before
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counterstaining with Haematoxylin. For anti-a-smooth muscle actin staining, slides were 
incubated with monoclonal primary antibodies (Sigma, St Louis MO) at a dilution of 
1:300 in 2% BSA and 0.04% sodium azide in PBS with anti-mouse immunoglobulin 
secondary antibody (‘Universal Link’, Biocare Medical, Walnut Creek CA) overnight at 
40 °C [117] to form immune complexes, which were applied to sections prepared as 
before overnight at 40 °C, then processed as above. Negative control slides were 
prepared in an identical way in the absence of primary antibody, and in addition, slides of 
mouse tibiae were stained for OC as positive control.
Statistical Analysis Comparisons across all groups together were
performed with ANOVA, and where significant trends were detected, significance was 
allocated to a specific group or groups by comparison to the control (Chow Sham) group 
using Dunnetts post hoc test of ANOVA. Comparisons between individual pairs of 
groups used student’s t-test Data are presented as mean ± SD. Analyses was performed 
on Instat statistical software.
3.3.3 Analysis of osteocalcin gene expression
Animals and diets. Six 10 week old Idlr1' mice were given either chow diet
or high fat diet for four weeks. At sacrifice under anaesthesia, organs were removed and 
flash-frozen in dry ice and ethanol slurry, then stored at -80 °C.
Reverse transcription polymerase chain reaction (RT-PCR). Messenger RNA 
(mRNA) was isolated using the RNAqueous-4PCR kit (Ambion), according to
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manufacturer's instructions. RT-PCR used the Onestep RT-PCR Kit (Qiagen, Valencia 
CA) according to manufacturer’s instructions, using the following primers for Murine 
osteocalcin: Sense: 5’ —CAAGTCCCACACACAGCAGCTT- 3’; Antisense: 5’ — 
AAAGCCGAGCTGCCAGAGCTGCCAGAGTT- 3’. Reaction conditions were: 50 °C 
for 30 min, 95 °C for 15 min, then 35-40 cycles of 94 °C for 1 min, 60 °C for 1 min & 72 
°C for 1 min, then 72 °C for 10 min. Negative control reactions were prepared by 
substituting an appropriate volume of deionised sterile water in place of RNA template.
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3.4 Results
3.4.1 Animals and groups
T he study was designed to sequentially enter animals into six groups (Table 3.1) as
follows: 5 animals in a chow-fed sham operated group (Group 1) as controls, and 10 
animals in each of five further groups (groups 2-6), receiving uraemic surgery (Groups 2, 
4 and 6), high fat diet (Groups 3-6) or BMP7 treatment (Groups 5 and 6). However, 
when some animals in groups 2, 3 and 4 (2, 3 and 1 respectively) did not survive surgery, 
it was decided to enter 12 animals in the final two groups (Groups 5 and 6). Two animals 
did not survive surgery in group 5, but all animals survived in group 6. This led to 
uneven numbers in each group. The higher than expected mortality was attributable to 
the surgical program, and may have reflected initial surgical inexperience of the 
researcher, but not to either the treatment regime or diet (Table 3.1). Approximately 
equal numbers of male and female animals were entered into each group to increase the 
applicability of results to the clinical environment Initial weights were comparable across 
all groups (Table 3.1). Untreated uraemic animals (Groups 2 and 4) tended to have a
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Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
Diet Chow Chow Fat Fat Fat Fat
Surgery Sham CRF Sham CRF Sham CRF
Rx - - Vehicle Vehicle BMP-7 BMP-7
n (Males) 5(2) 8(5) 7(4) 9(4) 10(5) 12(6)
Pre-Surgical 
Weight (g)
19.8 ±3.4 22.1 ±2.3 19.3 ±2.6 24.4 
±4.2
22.0 ±1.1 20.5 ±3.3
Sacrifice 
Weight (g)
24.8 ±4.0 22.3 ±2.1 25.0 ±3.9 26.2 
±5.4
*34.8 ±2.8 25.8 ±6.0
Post-
Surgical
BUN
(mg/dl)
24.2 ±5.2 b69.8 ±16.2 21.5 ±8.3 b86.0 
±12.1
23.8 ±5.0 b63.5
±16.4
Sacrifice
BUN
(mg/dl)
23.0 ±5.0 c76.5 ±11.0 25.5 ±6.6 c88.0 
±10.5
29.0 ±6.0 c71.9
±21.3
Total
Cholesterol
(mg/dl)
261 ±28 168 ±24 d1071 **940 
±370 ±386
d871
±192
d1097
±348
Glucose
(mg/dl)
172 ±31 183 ±21 192 ±23 190 ±46 211 ±66 197±59
Table 3.1 Biochem ical parameters of kU r/- m ice by experimental group. All values are
mean ± SD. BUN Cholesterol and Glucose are expressed as mg/dl. * Group 5 Sacrifice weight was h ig h e r  
than Group 1. b The CRF Groups 2, 4 & 6 had significantly higher Post Surgical BUNs than Group 1 
(P<0.01). cGroups 2, 4 & 6 have significandy higher sacrifice BUNs than Group 1 (P<0.01). dGroups 3 -  
6 had significandy higher Cholesterols than Group 1 (P<0.01).
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smaller weight gain than untreated non-uraemic animals (Groups 1 and 3), but these 
differences were not significant. Weight gain in the BMP7 treated Fat Sham animals 
(Group 5) was significantly greater than in other groups. Weight gain in BMP7 treated 
Fat CRF animals (group 6) did not differ from either untreated Fat CRF animals (Group 
4) or Chow Sham animals (Group 1). We did not observe any toxicity attributable to 
BMP-7 therapy.
3.4.2 Biochemical data
All animals undergoing uraemic surgery developed significant renal impairment, and
there were no significant differences in the degree of renal failure in CRF groups 
(Groups 2, 4 and 6) (Table 3.1). Renal function deteriorated during the treatment period, 
as evidenced by a rise in BUN between surgery and sacrifice (Median 5mg/dl, range —16 
to +75mg/dl); however the increment was small, and similar in magnitude to that in 
sham-operated animals (lmg/dl, range —5 to -l-14mg/dl). Animals fed the high 
cholesterol diet (Groups 3-6) were significandy hypercholesterolaemic compared to 
Chow fed animals (Table 3.1), and where observed to have dramatic atherosclerotic 
plaque formation in the proximal aorta compared to chow-fed animals. All animals had 
mild glucose intolerance, but this did not vary significantly across the groups.
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3.4.3 Histology
All of the Idlr1' animals fed the high fat diet developed an increase in the number and
size of atheromatous plaques of the proximal aorta and aortic arch. No difference was 
observed between male and female animals. Punctate calcification was seen in the aortic 
intima and media in all untreated groups (Figure 3.3 A-D). The high cholesterol diet 
produced severe atherosclerosis and calcification of aortic intima and media (Figure 3.3 C 
and D). Addition of CRF increased the number of punctate calcium deposits detected by 
the histological stain (Figure 3.3 E) compared to chow sham, group 1 (p<0.01, Table 
3.2). Calcification was strikingly reduced in BMP7-treated, Fat CRF animals (Group 6) 
(Figure 3.3. G and H). The extent of atherosclerosis (the number and size of 
atheromatous plaques) remained unchanged by BMP7 treatment. Scoring of the 
histological slides for the presence or absence of calcification confirmed these findings 
(Table 3.2). Total Calcification scores and scores for the Intimal vascular compartment 
were significantly higher in untreated Fat CRF animals (Group 4) than for Chow Sham 
animals (Group 1). These scores for Fat CRF animals treated with BMP7 (Group 6) 
demonstrate significantly less calcification than either Fat CRF vehicle-treated animals 
(Group 4) or Chow Sham animals (Group 1). Scores for the medial compartment 
revealed that BMP7 treated Fat CRF animals have significandy less calcification here 
than either untreated Fat CRF or Chow sham animals (Groups 4 & 1). There was a 
tendency towards reduction of vascular calcification by BMP7 on Fat Sham animals 
(Group 5 versus group 3), but this did not reach statistical significance. Our scoring 
system did not measure differences in size or number of calcifications between groups 
where calcification was present In particular, the effect of the fat diet to increase size of 
medial calcifications (Figure 3.3 C and D), and of CRF to increase the number of medial 
calcifications (Figure 3.3 E) were not measured in the scoring system, but this was
Groupl Group2 Group3 Group4 Groups Group 6
Diet Chow Chow Fat Fat Fat Fat
Surgery Sham CRF Sham CRF Sham CRF
Rx - - Vehicle Vehicle BMP-7 BMP-7
n 5 8 7 9 10 12
"'Total Score 3.6 ±1.6 3.8 ±1.0 4.4 ±2.1 a5.7 ±0.4 2.9 ±2.9 b0.5 ±0.5
B Intimal 
Score
1.0 ±1.3 1.2 ±0.9 2.0 ±1.3 C2.8 ±0.4 1.5±1.5 d0.1 ±0.2
cMedial
Score
2.6 ±0.4 2.6 ±0.4 2.4 ±1.0 f2.9 ±0.2 1.4 ±1.4 e0.4 ±0.5
Table 3 .2  Effect o f B M P -7  on aortic calcification scores by group. The m ax im u m  Total
calcification score is six, the sum of the maximum Intimal and medial scores. Three sections were analysed 
from each animal for the presence (one) or absence (zero) of calcification, yielding a m ax im al score of 
three for each compartment All values are mean ± SD, in arbitrary units (see text). “Total Score for group 
4 is significandy higher than for group 1 (P<0.01); b Total Score for group 6 is sign ifican tly  lower th a n  for 
group 1 (P<0.01) and group 4 (p <0.0001). cIntimal Score for Group 4 is significandy higher th a n  for 
Group 1 (P<0.01). ** In addition, the Intimal Score for group 6 is sign ifican tly  lower than Group 4 
(P<0.0002). * Medial Score for Group 6 differs from Group 1 (P<0.01). fGroups 4 & 6 differ from each 
other, P=0.0003.
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nevertheless the most objective system for scoring the effect of BMP7, which was to 
eliminate calcification (Figure 3.3 G-H, Table 3.2). Since no attempt was made to grade 
the severity of calcification histologically, specimens with a few small punctate lesions 
would score similarly to large areas of confluent calcification.
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Figure 3.3 E ffect o f  chronic renal failure (CRF) and bone m orphogenetic protein-7 (BM P7)
treatment on proxim al aortic calcification. Aortic outflow tract sections defined by two vascular walls 
and intervening aortic valves stained for calcification (Alizarin Red-S). Boxes in left-hand panels show area 
enlarged in corresponding right-hand panel. (A and B) Punctate intimal calcification in an area o f  plaque 
(arrows) in chow sham animal (group 1). (C and D) Intimal (arrows) and medial (arrowheads) calcification in 
fat sham animal (group 3). (E and F) Intimal (arrows) and medial (arrowheads) calcification in fat CRF 
vehicle animal (group 4). (G and H) Absence o f intimal or medial calcification in Fat CRF BMP-treated 
animal (group 6). Magnifications: 5 in A, C, E , and G; 10 in B; 20 in D , F, and H. Ao, aortic lumen; PI, 
intimal plaque; Med, layer; Va, Valve leaflet.
76
3.4.4 Immunohistochemistry
Osteocalcin is regarded as a marker of the osteoblastic phenotype.
Immunohistochemistry demonstrated low-grade baseline staining of vascular tissues in 
Chow Sham animals (Group 1) (Figure 3.4 B), compared to negative control (Figure 3.4 
A). OC staining was diffusely increased in Fat Sham (Group 3, not shown) and Fat CRF 
animals (Group 4, Figure 3.4 Q. In addition, OC staining was also noted on other tissues 
fortuitously on the same slides, including lung and oesophagus (not shown). In BMP7 
treated Fat CRF animals (Group 6), OC staining was gready reduced in vascular (Figure
3.4 D) and other tissues (not shown). This is in contrast to expression of aSMA, a 
marker of smooth muscle cell phenotype, which remained confined to smooth muscle 
layers in pulmonary and oesophageal tissues (not shown), for which immunostaining of 
vascular tissues was consistent across all experimental groups (Figure 3.4 E-H).
3.4.5 Reverse transcription polymerase chain reaction
T o  confirm the finding of widespread extra-osseous osteocalcin expression, we
extracted RNA from the organs of 14 week old Idlr1' mice fed chow or the high fat diet 
for four weeks, and performed RT-PCR. Osteocalcin mRNA was detectable in a number 
of organs in Idlr1' animals, and was found to be more widespread in fat fed animals 
(Figure 3.5). This confirmed the immunohistochemistry results that a previously 
unknown component of the Idlr1' phenotype is loss of tissue-specific expression of 
osteocalcin, which was restored by BMP7 therapy. However, tissues were not available
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Figure 3.4. Effect o f BMP7 on osteocalcin (OC) expression. Immunohistochemistry o f  proximal
aortic sections for O C (A through D, I) and a-sm ooth muscle actin (SMA)(E through H). (A) Negative 
control (vascular media, wild-type mouse); (B) medial OC expression (brown staining) in chow sham animal; 
(C) more intense medial and plaque OC staining in fat CRF animal; (D) striking reduction in medial and 
plaque OC staining in fat CRF BMP7-treated animal; (E) negative control for SMA. (F through H) Consistent 
medial SMA staining in chow sham (F), fat CRF (G), and fat CRF BMP7—treated animals (H). (I) Positive 
control: endochondral bone o f  EN AC overexpressing mouse tibial plateau, showing normal OC staining of 
mineralized primary and secondary spongiosa trabeculae and around hypertrophic chondrocytes, but not 
prehypertrophic chondrocytes or marrow space (I). Magnification, x20. Med,medial layer; PI, intimal plaque; 
Ao, aortic lumen. T rl , trabeculum in primary spongiosa; Tr2, trabeculum in the secondary spongiosum; HC, 
hypertrophic chondrocyte; PC, prehypertrophic chondrocyte; M, marrow.
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Chow
Figure 3.5 RT-PCR dem onstrates Osteocalcin mRNA at extraosseous sites. (Top panel) Samples
from a chow-fed L D L R -/- m ouse showing OC product at 370 bp in spleen and kidney samples. (Middle 
and bottom  panels) Samples from  two cholesterol-fed LD LR -/- mouse showing O C  product at 370 bp in 
liver, spleen, kidney, lung, heart, and aorta. Li, liver; Sp, spleen; Ki, kidney; Lu, lung; He, heart; Ao, aorta; 
Bl, blank; La, 100-bp ladder.
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to extend these results to CKD animals as these had already been committed to 
histological processing, and the effect of BMP7 on OC expression at the level of mRNA 
in this setting is not known.
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3.5 D iscussion
This study shows that the Idlr1' genotype in the C57/B16 mouse background is a suitable
model for the investigation of vascular calcification in the context of CRF, without the 
need for pharmacological manipulations used in other models [104-107]. While it is dear 
that atherosderosis in this modd is dependant on dietary manipulation, the diet used is 
nevertheless similar in composition to a ‘Western’ high fat diet, containing 0.15% 
cholesterol weight for weight and 42 % of calorific content as fat. The surgical technique 
used is analogous to the 5/6 nephrectomy modd in rats [112], and has previously been 
used to modd renal osteodystrophy in mice. In contrast to other models of uraemia, it is 
relativdy stable over time: it is debatable whether the small but statistically significant 
increase in BUN during the study is clinically significant, since a similar increase was 
observed in non-uraemic animals. In addition, the study shows that BMP7 is an 
efficadous treatment of Vascular Caldfication in the context of CRF and atherosderosis, 
an effect that appears to be general to both medial and intimal caldfication, although 
BMP7 treatment does not affect the extent of atherosderosis. The data concerning
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osteocalcin expression show that this osteoblastic protein is expressed in increased 
amounts in the calcifying milieu, and that its expression is reduced by BMP7 treatment
However, the histological data contains some inconsistencies that need explanation. 
Firsdy, it appears that in Fat-fed CRF animals (Group 6), BMP7 was able to reduce VC 
to levels lower than under non-uraemic baseline conditions (groups 1 and 3). There is no 
obvious biological rationale for this finding, and it is likely to reflect limitations of the 
calcification scoring system. The system is based simply on the presence or absence of 
calcification, but makes no attempt to grade different degrees of calcification where 
present, in order to maximise objectivity, and a consequence of this is that the difference 
in score between samples with small amounts of calcification, such as group 1, and 
samples with extensive calcification, such as groups 3 or 4, was minimized, but the 
difference between groups with small amounts of calcification and nearly none (Groups 
1 and 6) was exaggerated. The scoring system may also be prone to sampling errors that 
are difficult to quantify or control for. These limitations were therefore addressed in a 
further study, described below, in which total vascular calcification was quantified using a 
chemical technique.
A further inconsistency was the apparent lack of effect of BMP7 on vascular calcification 
in the absence of uraemia (Group 3 versus Group5). It is possible that the mechanisms 
underlying the calcification in the uraemic and non-uraemic situations may differ, with 
only uraemia-related disease amenable to BMP7 therapy, but it is also possible that the 
pharmacokinetics of BMP7 may be importantly different in the two setting. Firstly, 
animals in group 5 appeared to put on more weight than other groups, for reasons that 
aren’t clear (Table 3.1). Second, BMP7 therapy was given via the intraperitoneal route, 
and since it has been shown that peritoneal permeability is increased in uraemia [79], it is
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possible that uraemic animals absorbed a larger proportion of the delivered dose. 
Thirdly, BMP7 in the circulation is bound to a2-macroglobulin, which is in turn removed 
from the circulation in the liver by the receptor LRP1. Expression of this receptor has 
been shown to be increased in the context of the Idlr1' genotype in the absence of 
uraemia, and so BMP7 may be removed from the circulation more rapidly in this setting. 
Since the dose used was a small one, it may be that the combination of these factors has 
rendered the dose sub-therapeutic in non-uraemic Idlr1' animals. Further work is needed 
to clarify these issues.
Given the available data supporting the presence of a cell expressing an osteoblastic 
phenotype in the vessel wall [12, 39, 57, 118], it may seem paradoxical that a bone 
morphogenetic protein should reduce VC, given the known role of BMP7 in osteoblast 
biology. However it is clear that the effects of individual BMPs are highly dependent on 
the target cell type, the type of receptors that cell expresses, and its state of 
differentiation and maturity [79]. In this respect the nomenclature of these proteins based 
on their skeletal effects may be superficially confusing. Nevertheless, BMPs are critical 
morphogens in a wide range of tissue differentiation events, and BMP5, -6 and -7are 
clearly collectively critical for cardiovascular development. Important to understanding 
the data in this study is the data presented above that BMP7 has a positive influence on 
VSMC differentiation, and overall this study supports the hypothesis that 
transdifferentiation of VSMCs is the first critical step in the aetiology of vascular 
calcification. However, beneficial effects of therapy could be explained by other 
mechanisms such as secondary benefits of improved osteodystrophy, calcium phosphate 
homeostasis or perhaps nutrition in these uraemic animals, and these issues are also 
investigated further in the studies described below.
83
The data on osteocalcin expression are also somewhat unexpected. We chose to study 
osteocalcin because it is regarded as a marker of mature osteoblastic phenotype, and we 
anticipated that immunohistochemistry would reveal localised expression in relation to 
areas of calcification. However, the finding of widespread osteocalcin expression on IHC 
was supported by analysis of RNA from various tissues of the Idlr1' mice (Figure 3.4). We 
observed that osteocalcin was increased in fat-fed animals, in parallel with increased 
vascular calcification, and that both osteocalcin expression and VC are strikingly 
suppressed by BMP7 treatment. This suggests that the interpretation of osteocalcin 
expression as a unique marker for osteoblast function is overly simplistic. In fact the 
findings are consistent with the concept of osteocalcin as an endogenous limiter of 
calcification, expressed late in the osteoblastic gene program after mineralization has 
been initiated. The data presented above are consistent with an extended role beyond 
bone to other tissues including but not limited to the vasculature, with increased 
expression occurring under certain pro-calcific circumstances such as CRF, LDLR 
deficiency and high fat diet. Established data support this interpretation. In the mouse, 
osteocalcin exists in a three-gene cluster, OC1 and OC2, and the OC-related gene or 
ORG, which codes for the protein Nephrocaldn [119]. It has been shown that OC1 is 
strongly expressed in bone, and that OC2 and ORG are expressed elsewhere, albeit at 
lower levels. High structural homology between these proteins is consistent with 
functional homology, and they may be regarded as isoforms. All three bind to calcium 
ions via gamma-carboxylated residues, and act to limit the size of crystal formation. The 
phenotype oc A mouse includes an enlarged but otherwise normal skeleton [120], and 
Nephrocaldn expression by cells in the kidney tubule serves to limit renal stone 
formation [121]. Their high structural homology also makes it impossible to distinguish 
between the three gene products by conventional IHC or RT-PCR [122]. It is thus likely 
that the data in this study show an increase in expression of extra-osseous isoforms of
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OC in the face of the Idlr1' genotype and a pro-calcific environment caused by 
hypercholesterolaemia, atherosclerosis and CRF, and that BMP7 administration reduces 
expression of OC by ameliorating that pro-calcific tendency, by modifying the uraemic 
environment or preventing the initiation of the osteoblastic process. In this analysis, 
calcification of the vasculature in CRF represents a special circumstance, homologous to 
endochondral bone formation, where pro-calcific influences orchestrated by osteoblasts 
or osteoblast-like cells outweigh local anti-calcific mechanisms represented by osteocalcin 
and related proteins.
In summary, this study shows that BMP7 is an effective treatment of VC in the context 
of a murine model of atherosclerosis and CRF, but raises a number of further issues, 
including the relationship between vascular calcification and renal osteodystrophy, which 
are addressed below.
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Section 4
The relationship between vascular calcification and renal 
osteodystrophy in a murine model of atherosclerosis and 
chronic renal failure, and of the effect o f exogenous Bone 
Morphogenetic Protein 7 on these conditions
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4.1 Aim
T he study described in the previous section establishes the uraemic Idlr1' mouse as a
model of vascular calcification in chronic renal failure. However, as described above, the 
use of a histological system to assess vascular calcification is semi-quantitative at best, 
and the conclusions of the study would be strengthened by corroboration with 
alternative, quantitative methods. It is also clear that the effects of BMP7 on vascular 
calcification may be interlinked with its effects on bone. Thus, the present study was 
designed with the following specific aims:
• to quantify the degree of vascular tissue calcification previously defined 
histologically in section 4, using an analysis based on chemical quantification of 
total tissue calcium content
• to define the characteristics of renal osteodystrophy seen in the murine Idr1' 
model of atherosclerosis, uraemia and vascular calcification.
• to define the effect of BMP7 on both these pathologies in this setting.
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4.2 Introduction
4.2.1 Background and hypothesis
In  the previous study, vascular calcification (VC) was shown to increase when CRF was
superimposed on a murine model of atherosclerosis. In addition, this increase in VC was 
successfully ameliorated by intraperitoneal administration of exogenous BMP7. 
However, as discussed above, there are a number shortcomings inherent in assessing 
calcification by a histological scoring system, and it became clear that these results 
needed to be validated using a quantitative method. Thus, the intention of the present 
study was to assess VC using a chemical assay [104] to quantify total tissue calcium 
content in aortic tissues of Idlr1' mice exposed to the same experimental conditions.
A further aim was to assess the nature of renal osteodystrophy (ROD) in this model of 
VC. Abnormalities of calcium and phosphate ion homeostasis associated with VC such 
as hyperphosphataemia and elevated calcium/phosphate ion product (CaXP) are also 
characteristic of ROD. In addition, therapies used in the treatment of ROD, such as 
vitamin D analogues and calcium-containing phosphate binders, are also associated with
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the presence of VC [4,17]. It is thus reasonable to hypothesise a pathophysiological link 
between these two conditions. As noted above in Section 2.1.2.3, ROD comprises a 
spectrum of histological abnormalities, ranging from Osteitis Fibrosa characterised by 
high bone turnover, to Adynamic Bone Disease (ABD) characterised by low turnover 
[69]. While both forms of ROD may be associated with biochemical abnormalities 
relevant to the aetiology and progression of VC, it is likely that they do so by different 
mechanisms. While evidence now exists that BMP7 is effective in the treatment of both 
high [94] and low [74] turnover ROD in rodent models, this evidence with respect to 
ABD was not apparent at the time of design of the study. In any case, it was important to 
characterise the precise nature of ROD occurring in the present model if we were to fully 
understand the pathological processes involved in both the aetiology of VC, and the 
mechanism of action of BMP7 therapy in controlling VC in this setting. To do this, 
femurs and tibias were retrieved form experimental animals at sacrifice, and analysed by 
standard bone histomorphometric techniques that enable precise histological 
characterisation of ROD to be made in this model.
4.2.2 Bone remodelling
In  order to understand the histomorphometric analysis, it is important to understand 
normal processes involved in trabecular bone remodelling [115].
Normal trabecular bone is involved in a continuous process of remodelling, allowing 
renewal of trabecular structures and the maintenance of architectural integrity even after 
overall bone growth has ceased. This allows the skeleton to respond to external
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mechanical stresses by strengthening appropriate areas, but also contributes importantly 
to calcium, and to a lesser extent phosphate, homeostasis. Bone resorption occurs 
through the actions of multinucleated osteoclasts derived from monocyte precursors, and 
new bone matrix is synthesised and subsequendy mineralised by osteoblasts derived from 
mesenchymal precursors. In health, these processes are in balance, a situation 
orchestrated at the cellular level by osteoblasts through direct regulation of osteoclast 
maturation and function. Coordinated groups of osteoblasts and osteoclasts are referred 
to as a bone remodelling unit (BRU), which in turn acts to remodel a defined section of 
bone referred to as a bone structural unit (BSU). The BSU consists of a disc-like 
structure on the trabecular surface. Osteoclasts initially erode a pit at the leading edge of 
the BSU, and subsequendy pre-osteoblasts migrate into the pit before differentiating into 
mature osteoblasts. These mature osteoblasts then synthesise osteoid, which they 
subsequendy mineralise. The remodelling process may thus be divided into erosion and 
formation periods, separated by a quiescent period. Resorption is a more rapid process 
than formation. Approximately 4% of trabecular surface is undergoing resorption, 16% 
formation and 80% of trabecular bone is not involved in either process at any one time. 
In humans, the erosion period lasts approximately 43 days, the quiescent period 7 days 
and the formation period 145 days, giving a total of approximately 200 days for the 
whole process.
The total amount of bone remodelling occurring at any given time depends not only on 
osteoblast and osteoclast activity, but also on the total number of BRUs. The rate at 
which BRUs are formed is known as the activation frequency (Acf). This parameter is 
highly variable in bone diseases, and may have a large influence on overall bone turnover.
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4.2.3 Bone histomoiphometry
Bone histomorphometry is an established histological technique used to analyse static
and dynamic bone parameters in metabolic bone diseases of various types, through 
quantification of both directly measured and derived parameters of trabeculated and 
cortical bone. A detailed discussion of this technique is beyond the scope of this thesis, 
but a summary of the methodologies involved is included here and supported by a 
number of publications [114, 115, 152]. These measurements at a single point in time 
allow reconstruction of the recent remodelling cycle, through resorption, quiescence and 
then formation, a period of approximately three years in healthy human bone. For static 
parameters, histological sections of bone are stained in a standard way, to demonstrate 
the relevant cell types and structures, for example using Masson’s or Goldner’s 
trichrome. For dynamic measurements, the mineralising front is labelled at two points 
separated by a known period, and the spatial difference between the two labels assessed. 
Tetracycline is a commonly-used label as it autofluoresces, and dynamic measurements 
are thus made on unstained sections in this setting. Sections are then viewed under high 
power, through a superimposed grid, which intersects tissue structures in a random 
fashion. Morphometric methods used to analyse the sections rely on the application of 
probability theory and geometry, and use estimates rather than precise measurements. 
However, repeated counting ensures these estimates are highly accurate and robust. 
Defined tissue areas can be determined by point counting techniques, and measurements 
of distances or surfaces are made using the linear intercept method. These values are 
repeated then averaged over a number of sections. (See section 4.3.2 of specific 
methodology). While counting, measurement and calculation are carried out by 
computer, but the definition of structures to be assessed is a manual process. As such,
bone histomorphometry is a meticulous and time consuming technique requiring 
thorough training and expertise for consistent results. Thus, for reasons of quality and 
consistency, sections in this study were analysed by an investigator already experienced in 
the technique. Nomenclature and definition of the various parameters have been 
standardised by The American Society of Bone and Mineral Research, and these terms 
will be used in this thesis [114].
Tables 4.1 and 4.2 summarize some of the terms used, although this list is not exhaustive. 
Primary indices are directly measured, and include dynamic parameters measured from 
tetracycline or calcein double-labelling. These primary indices are then used to calculate 
secondary indices. As can be seen from Table 4.1, some parameters are quoted in both 
two- and three-dimensional formats. The rationale for this is that, while all measurements 
are actually performed in two dimensions, well-validated correlations exist between 
related two- and three-dimensional parameters, for example area and volume; thus a 
measurement in two-dimensional space can be confidently extrapolated to three 
dimensions. This allows appropriate ratios between different parameters to be derived: 
for instance the number of osteoblasts seen, NOb, can be related to bone perimeter, 
BPm, in two-dimensions, giving the parameter NOb/BPm, while the osteoblast surface, 
ObS, can be related to Bone Surface, BS, in three dimensions (ObS/BS).
Changes in bone histomorphometry seen in ROD are well described [69]. Osteitis 
Fibrosa is characterised by an increase in both bone formation rate and bone resorption, 
with an imbalance of osteoclastic activity leading to net bone resorption. As well as 
increased cellular activity, increased numbers of osteoblasts and osteoclasts are also seen, 
and there is evidence of peritrabecular fibrosis generated by functionally abnormal 
osteoblasts that have adopted a fibroblastic phenotype. Increased osteoblast activity also
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Index Type Measured
parameter
Name of Index Abbreviation 
3D 2D
Area & Area Bone Volume BV BAr
Volume Osteoid Volume OV OAr
Mineralised Volume MdV MdAr
Tissue Volume TV TAr
Perimeter & Length Bone Surface BS BPm
Surface Osteoid Surface OS Opm
Eroded Surface ES EPm
Osteoblast Surface ObS ObPm
Osteoclast Surface OcS OcPm
Labelled Surface LS LPm
(single, double) sLS, dLS sLPm,
dLPm
Width & Distance Mineralised Thickness MdTh MdWi
Thickness between Osteoid thickness OTh OWipoints or
lines Wall thickness WTh WWi
Label thickness LTh LWi
Number Number Osteoblast number - NOc
Osteoclast number - NOb
Table 4.1 Primacy Indices in Bone Histomocphometcy. See text for further explanation of terms
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Index Type Name of 
measurement
Abbreviation
Structural Trabecular Number TbN
Trabecular Separation TbS
Kinetic Mineralising Surface MS
Mineral Apposition Rate MAR
Osteoid Apposition Rate OAR
Bone Formation Rate BFR
Formation Period FP
Quiescent Period QP
Activation Frequency A ct
Table 4.2 Derived Indices in Bone Histomocphometty. See text fot further explanation of
terms.
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results in the presence of extensive unmineralised osteoid. A number of abnormal 
parameters, including the increased erosion surface, osteoclast number and extent of 
fibrosis all correlate to circulating parathyroid hormone levels, which are characteristically 
elevated in OF. Adynamic Bone Disease on the other hand is characterised by reduced 
bone formation rate and reduced osteoblast numbers. Osteoclast numbers and activity 
may be low or normal in this setting. ABD is differentiated from osteomalacia, another 
low-tumover bone disease sometimes seen in CRF, by the extent of unmineralized 
osteoid present: while osteoid dimensions are increased in Osteomalacia, they are usually 
normal in ABD. Clinically, some heterogeneity exists, and biopsies fall into a spectrum of 
diagnosis between these extreme points. In addition, serial biopsy studies have shown 
that individual patients may move from one condition to another during the course of 
their illness.
To enhance reliability and consistency, bone histomorphometry in this study was 
performed by a single operator (Dr R J Lund) blinded to the experimental grouping of 
the histological slides.
4.2.4 The animal model and the model of chronic renal failure
T he model of Id lr model atherosclerosis, CRF and vascular calcification was unchanged
from the previous study, and CRF was generated by the same surgical technique. It was 
expected that untreated uraemic mice fed the high cholesterol diet would develop OF, 
since their diet contained normal amounts of calcium and phosphate (1.0 and 0.65 %
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respectively) and the consequent secondary hyperparathyroidism would remain 
untreated.
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4.3 Methods
4.3.1 Animals and experimental procedures
Animals and diets. Experimental protocols involving animals and diets 
are as described in section 3.3.1.
Surged Procedures. Animals were rendered uraemic as described
previously in section 3.2 [112] (Figure 3.2). Control animals underwent sham operations, 
and intraperitoneal anaesthesia (xylazine 13mg/kg and ketamine 87mg/kg) was used for 
all procedures, including sacrifice. At sacrifice, the heart and aorta were dissected en bloc, 
to the iliac arteries. For chemical analysis, the aorta was separated from the heart at the 
level of the aortic valves, and then
further processed in its entirety. Both femurs and tibias were removed by dissection, and 
fixed in 70% ethanol at 4 °C.
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Treatment groups. We allocated animals to five groups (Table 4.2, Figure
4.1): Chow fed animals receiving sham surgery (‘Chow Sham’, Group 1); high 
cholesterol-fed animals receiving sham surgery(‘Fat Sham’, Groups 2 and 4)); and high 
cholesterol-fed animals receiving uraemic surgery (Tat CRF’, Groups 3 and 5). Groups 
other than control received either intraperitoneal BMP-7 (Curis Inc, Cambridge MA) 
lOpg/kg in 100 pi vehicle once weekly (Groups 3 and 5), or 100 pi vehicle alone Groups 
2 and 4). This treatment began on post-surgical day eight, the day after phlebotomy. The 
Chow sham group was included to define the bone parameters in the Idlr1' genotype 
under unmodified conditions. In contrast to the previous study, no chow fed animals 
were rendered uraemic. This avoided unnecessary sacrifice of animals, since it was felt 
that this group would be unlikely to contribute significandy to the interpretation of the 
study.
Blood tests. Blood samples were taken for biochemical assays prior to
initiation of BMP7 or vehicle therapy, and again at sacrifice, as above in section 3. In 
addition samples were taken at sacrifice for intact Parathyroid hormone assay. Serum was 
separated and stored at —80 C and assayed variously for blood urea nitrogen (BUN), 
cholesterol, calcium, phosphate, and glucose by standard laboratory methods. Intact 
Parathyroid Hormone levels were measured using a two-site immunoradiometric assay 
(IRMA) using a commercially available kit (Immutopics, San Clemente, CA, USA).
Statistical analysis. Comparisons across all groups together were
performed with ANOVA, and where significant trends were detected, significance was 
allocated to a specific group or groups by comparison to the control (Chow Sham) group 
using Dunnetts post hoc test of ANOVA. Comparisons between individual pairs of
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groups used student’s t-test. Data are presented as mean ± SD. Analyses was performed 
on Instat and SAS statistical software.
4.3.2 Tissue processing and analysis
Chemical quantification of aortic calcification. Aortic tissue from the outflow
tract to the iliac bifurcation was desiccated overnight at 55° C, weighed and crushed in a 
pestle and mortar. Calcium was eluted from this crushed tissue using 10% Formic add 
(10:1 v/w) for 24 hours at 4° C. The eluate was stored at -80° C until assayed. The 
caldum content of the eluate was assayed used a Cresophthalein-Complexone method 
(Caldum Kit, Sigma, St Louis), according to manufacturer’s instructions, and values were 
then corrected for dry tissue weight [104].
Bone Histomorphometry. For dynamic measurements, in vivo fluorescent
labelling of the mineralising front was achieved by intraperitoneal calcein injections, 
giving 20 mg/kg seven and two days prior to sacrifice. Femoral and tibial bone samples 
were dissected and fixed as above, and embedded undecaldfied in a plastic embedding 
kit H7000 (Energy Beam Sdences Inc, Agawam, MA USA) Tissues were sectioned in a 
frontal plane in 5 um sections, with a JB-4 Microtome, (Energy Beam Sdences, Inc) and 
stained with Goldner’s Stain for trabecular and cellular analysis. Tartrate-Resistant Add
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Idlr '- Mice weaned to Chow 
3 weeks
BMP-7 
13 weeks
BMP-7 
13 weeks
Vehicle 
13 weeks
Vehicle 
13 weeks
Chow Diet 
10 weeks
Sham Surgery 
10-12 weeks
Sham Surgery 
10-12 weeks
High Fat Diet 
10 weeks
Uraemic
Surgery
10-12 weeks
Sacrifice 
28 weeks
■— i n  ■ ■  ■ ' ■  " n ' l "  -= s = = ^ = s = :
Figure 4.1 Study design. Animals were sequentially entered into experimental groups on the basis of
diet, uraemic surgery and treatment. Experimental diets were commenced at the same time as the first uraemic 
surgery at 10 weeks. Second uraemic surgery was performed at 12 weeks. Experimental treatments were started 
one week after this, to allow animals to adequately recover from the surgical process. See text for full 
description.
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Phosphatase (TRAP) staining was used to identify osteoclasts and define osteoclast 
surfaces. Unstained lOum sections were used for calcein-labelled fluorescence analysis. A 
reticulin stain was used for assessment of peritrabecular fibrosis. Slides were examined at 
x400 magnification using a Leitz microscope attached to an Osteomeasure Image 
Analyser (Osteometries, Atlanta, GA, USA). Ten contiguous 0.0225mm2 fields of the 
proximal tibia 150um distal to the growth plate (to exclude secondary spongiosum) were 
examined per animal. Primary, derived and dynamic measures of bone remodelling were 
reported as per the guidelines of the American Society of Bone and Mineral Research.
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4.4 Results
4.4.1 Animals and groups: biochemical data
Five animals were entered into each group in this study. All animals survived the surgical
procedures and experimental protocol, likely to reflect improved surgical technique. 
There were small non-significant differences in weight gain throughout the study 
between groups. No toxicity attributable to BMP-7 therapy was observed.
All animals undergoing uraemic surgery developed significant renal impairment, and 
there were no significant differences in the degree of renal failure in CRF groups 
(Groups 4 and 5) (Table 4.3). Renal impairment was maintained throughout the study 
period in these groups. Animals fed the high cholesterol diet (Groups 2-5) were 
significantly hypercholesterolaemic compared to chow fed animals (Table 4.3). All 
animals had mild glucose intolerance, but this did not vary significantly across the
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Group 1 Group 2 Group 3 Group 4 Group 5
Diet Chow Fat Fat Fat Fat
Surgery Sham Sham Sham CRF CRF
Rx - Vehicle BMP7 Vehicle BMP-7
n 5 5 5 5 5
Pre-Surgical 
Weight (g)
21.7 ±2.2 21.1 ±2.2 20.3 ±2.9 21.6 ±2.7 23.7 ±2.3
Sacrifice 
Weight (g)
22.6 ±2.6 24.7 ±5.7 20.7 ±3.7 21.4 ±3.4 23.3 ±3.6
Post-
Surgical
BUN (mg/ dl)
26.9 ±7.4 25.4±5.6 34.3 ±6.8 *95.7±22.8 *77.9 ±10.1
Sacrifice
BUN
(mg/ dl)
36.9 ±5.4 26.4 ±6.7 53.2 ±56.9 73.1 ±2.6 102.5 ±35.5
Total
Cholesterol
(mg/dl)
494.3 ±40.5 c2249.8
±816.8
C1784.8 
±476.7
C1462.0 ±51.5 C1986.0 
±1120.7
Glucose
(mg/dl)
289.3 ±91.6 209.0 ±63.6 219.0
±67.1
240 ±107.1 194.5 ±44.7
Calcium
(mg/dl)
8.4 ±1.5 8.2 ±1.5 10.2 ±1.7 9.8 ±0.6 10.5 ±4.7
Phosphate
(mg/dl)
9.4 ±0.4 12.2 ±4.2 11.1 ±0.7 12.4 ±2.8 10.2 ±1.0
PTH
(pg/dL)
30.0 ±26.7 28.4 ±28 85.2
±159.9
209.6 ±187.7 268.6
±335.7.
Table 4.3 Biochemical parameters of ld lr '-  m ice by experimental group. Values are expressed as 
mean i  SD. * The CRF Groups 4 & 5 had significantly higher Post Surgical BUN values than Group 1 
(P<0.01). b Groups 4 & 5 had significantly higher sacrifice BUN values than Group 1 (P<0.01). c Groups 
2-5 had significantly higher Cholesterol values than Group 1 (P<0.01).
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groups. Calcium and phosphate data showed variability between groups; however, wide 
confidence intervals mean that no differences were significant. This may reflect sample 
size. Animals with CRF (groups 4 and 5) had higher PTH levels than non uraemic 
animals, but once again, wide confidence intervals mean that these differences are not 
significant (Table 4.3). In fact, with respect to PTH the most striking change in these 
animals with CKD is the increase in range and variability of values measured (Figure 4.2).
4.4.2 Chemical quantification of aortic calcification
This assay quantifies total tissue calcium content. We assumed that intracellular calcium
content was identical in all groups, and that differences detected between groups reflect 
differences in extent of extracellular calcium deposition. Baseline levels of calcification 
were defined in Chow Sham animals (Group 1) (Fig. 4.3), and a non-significant two-fold 
increase was detected in Fat Sham animals (Group 2). BMP-7 therapy had no effect on 
calcification in Fat Sham animals (Group 3). The aortas of the Fat CRF animals (Group 
4) had a significant increase in calcification, approximately 6 fold over Chow Sham 
animals. BMP-7 therapy of Fat CRF animals reduced calcification (Group 5), and calcium 
levels in this group are not different statistically from Chow Sham animals (Group 1).
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Chow Sham Fat Sham Vehicle Fat Sham BMP7 Fat CKD Vehicle
Group
1
Fat CKD BMP7
Figure 4.2 Parathyroid Hormone levels in l d h r m ice. Serum Parathyroid Hormone level at
sacrifice by group (mean ± SD). No significant differences between groups
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Fat CKD 
Vohido
Fat CKD 
BMP-7
Figure 4.3 Chart showing chem ical assessm ent of effect of BMP-7 on vascular 
calcification by treatment group. Total aortic calcium content measured in a 10% formic acid 
eluate of crushed desiccated aorta. Data are mean ± SD. Trend is significant by ANOVA, P = 0.008. 
* Fat-fed uraemic animals treated with vehicle have significandy higher levels than chow-fed sham 
controls. (P < 0.01, by Dunnetts post hoc test.) Fat-fed uraemic animals treated with BMP-7 are 
indistinguishable statistically from control (chow sham animal).
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4.4.3 Bone histomorphometry
T he most striking bone histomorphometric findings concerned osteoblast-related bone
formation parameters in uraemic animals receiving vehicle (Group 4). The number of 
osteoblasts per field (NOb) was significantly reduced compared to control animals 
(Groupl) (Figure 4.4A), and this remained true when expressed in relation to the defined 
tissue area (NOb/Tar) (Figure 4.4 B), or bone perimeter (NOb/BPm) (Figure 4.4 C). 
Consistent with this, the osteoblast surface as a proportion of bone surface (ObS/BS) 
(Figure 4.5A) was reduced, and indices of the bone formation component of the 
remodelling cycle were appropriately perturbed: the proportion of bone surface that is 
mineralising (MS/BS) (Figure 4.5 B) and calcein-labelled (LS/BS, Figure 4.5 C) were 
both reduced, and the formation period (FP) and quiescent period (QP) were both 
lengthened (Figure 4.6 A & B). Measures of overall bone structure reflect this reduction 
in bone formation: Bone perimeter (BPm) (Figure 4.6 C) and trabecular number (TbN) 
are reduced, and trabecular separation (TbS) is increased (Figure 4.7 A & B). The total 
amount of bone surface in relation to the tissue volume (BV/TV) was also reduced 
(Figure 4.7C).
In contrast, Osteoclast numbers (NOc) were not significantly different between groups, 
and nor were parameters of bone resorption such as Activation frequency (Acf) or 
eroded surface in relation to bone surface (ES/BS) (Table 4.4). Osteoid parameters, such 
as thickness, volume and proportion of bone surface (OTh, OV/BV, and OS/BS) were 
also indistinguishable from control (Table 4.4). These findings are all consistent with an 
Adynamic Bone Disease.
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Chow Sham Fat Sham Fat Sham Fat CKD Fat CKD 
Vehicle BMP7 Vehicle BMP7
Nob/TAr
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Figure 4.4 Bone histomorphometry: comparison between groups of osteoblast numbers expressed alone 
(A), related to tissue area (B) and bone perimeter (C) (mean ± SD). * p < 0.001; f  p < 0.02; $ p < 0.005 
versus Chow Sham.
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AChow Sham Fat Sham 
Vehicle
Fat Sham 
BMP7
Fat CKD 
Vehicle
Fat CKD 
BMP7
B
MS/BS
Mi l l
Chow Sham Fat Sham Fat Sham Fat CKD Fat CKD 
Vehicle BMP7 Vehicle BMP7
C how  Sham  Fat Sham  Fat Sham  Fat CKD Fat CKD 
Vehicle BMP7 Vehicle BMP7
Figure 4.5 Bone histomorphometry in ld lr /m mice. Comparison is made between experimental 
groups of osteoblast surface (A), mineralising surface (B) and labelled surface (C), all related to bone surface 
(mean ± SD). * p < 0.01 versus Chow Sham
With respect to the effects of BMP7 in this setting, it is notable that in the fat CRF group 
treated with BMP7 (Group 5), none of the parameters that are abnormal in the untreated 
group (Group 4) are significantly different from control (Group 1) (Figures 4.4-4.6, 
Table 4.4), suggesting that in this setting BMP7 prevents ABD.
Data in groups 1-3 define the baseline bone histomorphometry of the fat-fed animals 
without CRF, and their response to BMP7. In considering parameters related to bone 
formation (Figure 4.3), NOb and NOb/TAr are reduced in untreated fat-fed animals 
(Group 2) .While osteoblast number expressed in relation to bone perimeter (NOb/BPm) 
is also less than control, the difference does not reach statistical significance (Figures 4.3 
Q. While a number of other parameters differ from control in a manner consistent with 
an adynamic state (ObS/BS, BPm, TbN and BS/TV are reduced; FP, QP, and TbS are 
increased (Figures 4.4-4.6)), none of these differences are statistically significant. 
Parameters relating to Osteoclasts and bone resorption, as well as osteoid parameters are 
also no different to control (Table 4.4) in these non-uraemic groups. Taken together, 
these findings in the fat-fed untreated animals with normal renal function are consistent 
with a mild adynamic condition, although caution is needed in drawing this conclusion.
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Figure 4.6 Bone histomoiphometty in I d l r mice: comparison between experimental groups of
formation period (A), quiescent period (B) and bone perimeter (C) (mean ± SD). f  p = 0.001, * p < 0.01 
versus Chow Sham.
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Figure 4.7 Bone histomorphometry in ld lr^ ' mice: comparison between groups of trabecular
number (A), trabecular surface (B) and bone surface related to tissue volume (Q (mean ± SD). f  p= 0.02, * 
p < 0.01 versus Chow Sham.
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Parameter
Group 1 Group 2 Group 3 Group 4 Group 5
Diet
Surgery
Rx
Chow
Sham
Fat
Sham
Vehicle
Fat
Sham
BMP7
Fat
CRF
Vehicle
Fat
CRF
BMP-7
NOc (n) 6.0 ±1.2 5.8 ±0.5 6.2 ±1.6 5.2 ±1.58 6.0 ±0.7
ES/BS (%) 12.3 ±4.5 17.3 ±5.9 10.2 ±3.0 12.5 ±4.8 8.4 ±2.0
OTh (uM) 1.3 ±0.3 1.3 ±0.2 1.2 ±0.3 2.1 ±0.7 1.5 ±0.9
OV/BV(%) 1.0 ±0.4 0.7 ±0.4 0.6 ±0.3 2.0 ±1.4 1.0 ±0.7
OS/BS(%) 13.2 ±5.2 9.0 ±3.4 10.0 ±3.5 15.5 ±7.8 12.3 ±9.7
Acf (f1) 54.1 ±11.1 43.4 ±43.0 35.8 ±11.1 17.6 ±5.3 48.6 ±17.2
Table 4.4 Results of selected bone histomotphometric parameters. Data expressed as mean
+ SD. There are no significant differences between groups for these parameters.
114
4.5 D iscussion
4.5.1 Vascular calcification
The results of the current study complement the findings described in Section 3. They
confirm firstly that VC is significandy increased in the context of CRF in this model, and 
also confirm the important finding that BMP7 therapy is able to prevent this change. The 
methodology used in this study is quantitative, and entirely objective. Whereas the 
histological data presented above concentrated on the proximal aorta from the aortic 
valves to the beginning of the descending aorta, the current data reflects the state of 
calcification of the whole aorta from the aortic valves to the iliac bifurcation. Thus, these 
findings counter concerns that the previous histological results might have been subject 
to either sampling errors or observer errors by the scorers. We have assumed that 
intracellular calcium is identical in all samples, and that changes measured in tissue 
calcification reflect differences in extracellular mineralisation. While evidence shows that 
changes in extracellular calcium and phosphate concentrations may promote expression 
of the osteoblastic phenotype in these cells, it has not been shown that intracellular ion 
changes are essential to this. While it is therefore possible that the measured changes in
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tissue calcium content in YC include a component of intracellular change that thus far 
remains unquantified, it is nevertheless likely, given the striking histological changes seen 
and the density of calcium ions in hydroxyapatite, that the majority of the measured 
changes do indeed reflect extracellular mineralisation.
4.5.2 Bone histomorphometry and renal osteodystrophy
T he bone histomorphometry data in this study clarify the nature of renal bone disease in
the Idlr1' model of vascular calcification and uraemia, and clearly show that uraemic 
animals fed a high fat, high cholesterol diet have a low-tumover bone turnover state 
characterised by reduced osteoblast numbers and function (Group 4). These 
histomorphometric findings are highly congruent with changes seen in adynamic bone 
disease in humans [69]. It is interesting to note that even in animals with normal renal 
function (group 2), a number of findings in osteoblastic parameters suggest that there 
may be a tendency to a low turnover state in Idlr1' mice fed a high fat diet, when these 
animals are compared to chow-fed controls. These are unexpected findings. The initial 
assumption when this study was being designed was that untreated uraemic animals 
would have a high-tumover bone disease consistent with OF and secondary 
hyperparathyroidism, since this is found in other mouse models of uraemia [94], and is 
the commonest histological diagnosis noted in early bone biopsy series in uraemic 
human subjects [69, 72]. While rodent models of adynamic bone disease do exist, these 
involve additional intervention beyond the imposition of uraemia itself, such as either 
Vitamin D therapy [74] or dietary supplementation with calcium to act as a phosphate 
binder [123]. The animals in the present study received no supplementary Vitamin D,
and the calcium content of the high fat diet is comparable with standard laboratory 
chow; thus other explanations of this finding need to be sought In this respect, it is 
worth considering that not all human subjects with untreated uraemia develop high 
turnover bone disease. A percentage of subjects in biopsy studies have adynamic bone 
disease [72], and the factors responsible for this are not clearly known. However, it is 
likely that this heterogeneity in bone disease reflects underlying metabolic and genetic 
heterogeneity in the population studied, and therefore the particular genetic and 
metabolic phenotype of the Idlr1' mouse model may include a combination of factors that 
predispose to the occurrence of an adynamic bone disease in the context of uraemia. 
Certainly diabetes mellitus has been linked to ABD, and also to low bone turnover states 
in the absence of uraemia, and undoubtedly fat-fed Idlr1' mice are glucose intolerant In 
addition, it is possible that the dyslipidaemia seen in this model may be important to the 
aetiology of ABD since Demer and colleagues have proposed a link between elevated 
oxidised lipid fractions, in particular LDL, and the presence of osteoporosis [124], 
another bone disease characterised by low bone turnover. Clearly in the Idlr1' model, 
LDL fractions will be elevated, and in the context of uraemia, these are likely to be 
oxidised, since this process is increased in uraemia.
Undoubtedly, further investigation is needed to clarify these issues. Nevertheless, on the 
evidence of this study the Idlr1' uraemia mouse is characterised as a model of 
spontaneous adynamic bone disease without the need for further manipulation beyond 
the imposition of uraemia.
The second important finding of the histomorphometry data is that the low-tumover 
state seen in fat uraemic animals is entirely reversed by BMP7. This is consistent with 
known functions of BMP7 in the normal differentiation and maturation of osteoblasts
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[80, 125], given that the histomorphometric abnormalities in ABD are predominantly of 
osteoblastic parameters and bone formation. This is an important finding, and 
complements previous results showing that BMP7 is an effective therapy of high 
turnover bone disease [94] and an alternative model of the ABD [74] in mice. This 
finding emphasises that both types of bone disease are characterised by abnormalities of 
osteoblast function. In OF, dysregulation of OB function leads to over-activity of 
osteoclastic bone resorption and marrow fibrosis, while in ABD the failure of osteoblasts 
to differentiate and mature, leads to low bone turnover. Importandy, both studies 
demonstrate that normalising osteoblast function permits normal bone turnover and 
structural integrity, strongly suggesting that the documented osteoblast abnormalities are 
initiating events, rather than consequences of other pathological processes. It is 
interesting to note that this benefit occurred without clearly improving 
hyperphosphataemia or hyperparathyroidism in these animals and this indicates that the 
processes of secondary hyperparathyroidism and ROD may not be inextricably linked. 
This raises the possibility of alternative therapeutic approaches to the problem of ROD 
in the clinical arena in the future.
4.5.3 Bone biochemistry and parathyroid hormone
The presence of adynamic bone disease is important when analysing bone chemistry and
PTH data. The mean PTH level is increased in uraemic animals (Groups 4 and 5), but 
wide confidence intervals are seen, and differences between these groups and control are 
not significant. Perhaps the most striking finding is the wide range of values: some are 
elevated, some nearly normal. This finding largely reflects the known clinical condition of
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ABD, where PTH levels are not as consistently elevated as they are in OF, and may be 
normal in some subjects. It should be noted that there is no dear difference for PTH 
levels between groups 4 and 5, suggesting that the beneficial effects of BMP7 on bone 
histomorphometric parameters are independent of any changes in parathyroid hormone 
levds.
With respect to caldum and phosphate levds, it is difficult to make out a clear pattern of 
variation, and confidence intervals are again wide. A number of factors may be rdevant 
to this finding, including the presence of ABD. As noted previously, one consequence 
of the presence of a low bone turnover state is the reduction in size of the rapidly 
exchangeable ion pool, which has important consequences for buffering serum caldum 
and phosphate levds. This may be particularly important in the post-prandial setting. 
Animals in this study were not fasted prior to sacrifice, and so it is possible that the 
variability seen reflects underlying lability of serum concentrations of these ions. This on 
the other hand may be important in the aetiology of vascular caldfication, in that the 
initiation of osteoblastic transdifferentiation of VSMCs has been linked to phosphate 
concentrations [50, 68], and peak phosphate concentration may be as detrimental as 
steady state levd in this context. Secondly, heterogeneity in PTH levds and 
hyperparathyroidism may contribute to the variance observed in these ion levds. A third 
factor is that no assessment has been made of Vitamin D status of these animals. The 
uraemic animals are presumed to be defident of Vitamin D, in keeping with the extent of 
their renal failure, but levels were not measured to confirm this. It is therefore possible 
that the differences in the extent of renal impairment between individual animals within 
groups 4 and 5 could lead to physiologically different levels in Vitamin D, leading to 
variance in serum caldum and phosphate levds. A final issue rdevant to variability in 
phosphate levels in particular is the possibility of haemolysis during blood sample
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retrieval by ventricular stabbing. Haemolysis releases intracellular contents, including 
phosphate, and a small amount of haemolysis is likely to occur even in carefully drawn 
samples, particularly in uraemic subjects in whom red cell fragility is increased. However, 
this factor was not obvious on inspection of plasma after separation, and although 
difficult to quantify, is likely to be small. Since all uraemic groups have blood drawn 
under similar conditions irrespective of BMP7 therapy, this effect is controlled for.
In summary, the present study addresses three issues. Firstly, it confirms the histological 
data presented in section 3, showing that aortic calcification is increased in the context of 
CRF superimposed on atherosclerosis in the Xdlr1' mouse. This confirmation, using an 
established chemical assay of whole-tissue calcium content, is entirely quantitative and 
therefore these data are more robust than in the previous study. Secondly, this study 
defines the nature of the renal osteodystrophy associated with CRF in this model, and 
characterises it as an adynamic bone disease. Thirdly, the study demonstrates that 
exogenous BMP7 administration is able both to counteract the vascular calcification and 
to prevent the osteodystrophy observed in this setting. This finding lends further support 
to the concept of chronic kidney disease as a state of BMP7 deficiency, and to the idea 
that many of the clinical manifestations of the uraemic syndrome derive directly from 
this.
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Section 5
The effect of Bone Morphogenetic Protein 7 on calcifying 
vascular cells, an in vitro m odel of vascular calcification
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5.1 Aim
T he findings described in Sections 3 and 4 have established that exogenous BMP7
administration prevents vascular calcification (VC) in uraemic Idlr1' mice. At the same 
time, BMP7 is able to ameliorate the adynamic renal osteodystrophy (ABD) inherent in 
this model by normalising osteoblast function. This effect may in part explain the 
beneficial effects of BMP7 on VC through its consequent effects on extracellular calcium 
and phosphate concentrations. Nevertheless, other lines of evidence suggest that BMP7 
may have direct beneficial effects on vascular smooth muscle cell (VSMC) biology that 
serve to reduce VC independent of its effects on bone mineralization. Thus, the studies 
in this chapter aim to test this hypothesis in an established in vitro model of VC, the 
Calcifying Vascular Cell (CVQ.
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5.2 Introduction
5.2.1 Background
As previously discussed in Section 2, the transdifferentiation of VSMCs into an
osteoblastic phenotype has emerged as a central mechanism in the pathophysiology of 
VC. Several studies have documented increased expression of osteoblastic proteins in 
vascular tissues in the context of VC [36, 37, 39, 43-49], and similar expression patterns 
have been demonstrated in smooth muscle cells derived from healthy vascular tissues 
when studied ex vivo under various conditions [52, 53]. In one study, Dorai showed in 
VSMCs that TGF|3 is able to increase expression of the Collagen I gene [67], a protein 
associated with osteoblast but not smooth muscle extracellular matrix. At the same time, 
expression of genes for typical smooth muscle proteins collagen III and a Smooth 
Muscle Actin (aSMA) was decreased [67]. Importantly, these changes were prevented by 
co-administration of BMP7 in a Smad6-dependant manner, suggesting that BMP7 may 
play a role in maintaining the normal integrity of VSMCs and that its absence may 
facilitate the emergence of an osteoblastic phenotype in these cells conducive to VC. 
This may particularly be so under conditions of inflammation when increased levels of
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TGFp may be present. Several other lines of evidence exist supporting this concept that 
imbalance between TGFp and BMP7 may be important in the osteoblastic 
transformation of VSMCs and their subsequent ability to mineralize their extracellular 
matrix. Firsdy, TGFp has been shown to promote extracellular mineralization by CVCs 
in vitro [57]. As discussed previously in Section 2.1.2.1, these cells have been derived 
from the medial layer of arteries from healthy animals in a number of species, and share 
characteristics of both osteoblasts and smooth muscle cells. Thus CVCs putatively 
represent a subgroup of VSMCs that have undergone a process of transdifferentiation, 
and have emerged as a useful in vitro model of vascular calcification. Nevertheless, not all 
VSMC have this propensity, although the reasons for this are not clear. Secondly, smadS1' 
mice develop spontaneous aortic calcification, which supports the concept that the 
interaction between BMP7 and Smad6 is physiologically important in maintaining VSMC 
integrity and preventing VC [101]. Thirdly, VC is highly prevalent in CKD, and this 
setting is increasingly becoming characterised as one of relative BMP7 deficiency. This is 
based on the observation that BMP7 expression is decreased soon after renal injury [75, 
76, 90], and supported by data from studies showing that exogenous BMP7 
administration improves a number of aspects of renal failure and uraemic syndrome in 
animals with renal impairment [74, 90-92, 94,126,127].
However, there are no studies to date looking at the effects of BMP7 on calcification 
itself by vascular cells in vitro, and the studies described in this chapter aimed to address 
this issue.
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5.2.2 The model
T he derivation and investigation of CVCs were first described by Demer’s group [39],
and have subsequently been extensively studied by other investigators [50, 51] (see 
section 2.1.2.1). Cells are derived from explants of the medial layer of aortic tissue from 
healthy adult animals of various species, and propagated by standard cell culture 
techniques. Cells are identified as VSMCs rather than other cells of vascular origin on 
morphological and immunohistochemical grounds, and are not associated with 
extracellular calcification. Once these VSMC cultures have progressed to confluence, 
cells draw themselves up into a characteristic hill-and-valley morphology, and nodules of 
calcification typically appear on the summits of these hills of cells over a period of two to 
three weeks in standard culture conditions. The cells associated with the calcified nodules 
are then separated from uncaldfied areas of the culture, as well as from the nodules 
themselves, and may be further propagated. Subsequent generations of these cells 
continue to calcify their extracellular matrix spontaneously and express the range of 
osteoblastic genes previously discussed. It is these cells that are termed CVCs. Thus, 
CVCs are effectively VSMCs selected preferentially for their ability to calcify their 
extracellular matrix, and which show evidence of having transdifferentiated into an 
osteoblastic phenotype.
CVCs are relatively easy to derive, and can be sustained in culture in straightforward 
media such as Dulbecco’s Modified Eagle Medium (DMEM) with 10 - 15% serum, 
without the need for supplementation with growth factors. They have been extensively 
investigated in a number of studies that have characterised the conditions under which 
calcification occurs (summarised in Table 2.1), as well as the nature of osteoblastic 
transformation of these cells in terms of gene expression. Included among the factors
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causing increased calcification by CVCs are TGF6 [57] and both organic and inorganic 
phosphate [50, 58, 68]. Since hyperphosphataemia is a common finding in CKD which 
has been correlated to the presence of VC, and since increased TGF6 expression is 
implicated in the progression of a number of renal diseases, these findings suggest that 
CVCs are a suitable model of VC in CKD in which to investigate the role of BMP7. 
While CVCs have been derived from a number of different species including humans, 
bovine cells have emerged as pre-eminent due to their ease of derivation and stability in 
culture up to 20 passages, and are the species studied in most of the studies noted above. 
Bovine CVCs were thus chosen for these experiments.
127
5.3 M ethods
5.3.1 Cell culture and media
Bovine CVCs were a gift from the laboratory of Dr Linda Demer (UCLA), and derived
from aortic media of healthy adult cows as previously described [39, 57]. Cells were 
stored in liquid nitrogen until required for use. Cells were used between passage 13 and 
18, propagated in T75 flasks under aseptic conditions, and incubated at 37 °C in an 
atmosphere supplemented with 5% COz. Cells were passaged at confluence by 
incubation in 0.5% trypsin inO.2% EDTA for 3-5 minutes at 37 °C followed by 
filtration of the cell suspension through a 40 pm pore filter (Fisher Scientific, Pittsburgh) 
to remove calcified nodules, before either storing at -80 °C, seeding further flasks as 
above split in a ratio of 1:7. For experimental protocols, cells were seeded into 12 well 
plates at a density of 105 cells/cm2. For immunohistochemistry, cells were grown on 
sterilised glass cover-slips placed in the wells.
Basic media used for cell propagation and as control medium in experimental protocols 
was DMEM with 0.45% glucose (Product D5648, Sigma, St Louis), supplemented with
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10% Foetal Bovine Serum, ImM Sodium Pyruvate, Penicillin 100 units/ml and 
Streptomycin 100 Mg/ml. Media was routinely changed every second or third day. In 
experimental protocols, 10 mM [3-glycerophosphate ((3GP) was added to the culture 
medium as an organic source of phosphate ions (‘Calcifying medium5). Previous studies 
have shown that (3GP promotes mineralization by CVCs in a dose-dependant fashion up 
to a concentration of 10 mM [51], and has been widely used to promote extracellular 
calcification of osteoblastic cultures [116]. Where indicated, BMP7 was diluted to 
concentrations of 0.1, 1.0 and 10 ng/ml in manufacturer's specified vehicle (20mM 
acetate, 5% Mannitol at pH 4.5) and added to the basic or calcifying culture medium 
immediately prior to its application to cells. In addition, vehicle was added to media, 
where indicated, to act as a treatment control. Media was changed every second day 
during experimental protocols, and BMP7 or vehicle added at the same time. Each 
treatment was performed on six samples per experiment, and repeated twice.
5.3.2 Calcification assays
For histological assessment of calcification, cell layers were stained with Alizarin Red-S.
Cells were washed in PBS after removal of culture medium, and fixed in 4% 
formaldehyde freshly prepared in PBS for 30 minutes. Cells were further rinsed in PBS, 
washed in deionised water, and then incubated with Alizarin Red-S 5 mg/ml titrated to 
pH 4.2 at room temperature for 15 minutes. Cells were rinsed again in deionised water, 
before the stain was developed in PBS for 20 minutes. Finally, cells were dehydrated in 
100% ethanol and allowed to air dry.
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Calcification was quantified by chemical assay of total extracellular calcium deposited on 
cell layers, and corrected for total protein content. Culture media was aspirated at the end 
of each experiment and unfixed cells were washed in phosphate-buffered saline (PBS), 
and then incubated in 0.6N Hydrochloric Add (HC1) overnight at 4 °C to elute caldum. 
This eluate was removed and stored at -80 C until assayed using the Complexone assay 
system (Caldum Kit, Sigma, St Louis) according to manufacturer’s instructions. 
Following removal of the caldum-containing eluate, cells were further washed and 
solubilized in 0.1 N Sodium Hydroxide (NaOH)/ 0.1% SDS. This lysate was also stored 
at -80 °C until assayed for protein content using the DC Protein assay kit (Biorad) 
according to manufacturer’s instructions.
5.3.3 Immunohistochemistry
Cells were washed in PBS and fixed in fresh 4% formaldehyde, as above. After rinsing in
PBS, cells were incubated with 50mM freshly made Ammonium Chloride (NH4C1) for 15 
minutes at room temperature to quench aldehyde groups and reduce background tissue 
fluorescence, then rinsed again in PBS. To expose intracellular epitopes (eg aSMA) cells 
were permeabilized by incubation with 0.2% Triton X-100 in PBS for 15 minutes at 
room temperature. Non-spedfic antibody binding was blocked with a 30 minute 
incubation with 2% bovine serum albumin (BSA) and 0.04% sodium azide in PBS at 
room temperature, or 2% BSA, 0.04% sodium azide and 0.1% Triton X-100 in PBS if 
cells had previously been permeabilized. Cells were incubated with primary antibody 
diluted 1:200 (aSMA) and 1:300 (3G5) in 2% BSA and 0.04% sodium azide in PBS for 1 
hour at room temperature, washed in PBS, then incubated with secondary antibody
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(Indocarbocyanine (Cy3)-conjugated Immunoglobulin G (IgG)) diluted to 1:200 in 2% 
BSA and 0.04% sodium azide in PBS for a further hour. Cells were washed in PBS and 
mounted on microscope slides with Aqua Polymount, then viewed on a Zeiss 
Fluorescent Microscope, and results recorded digitally. Control cells were incubated as 
above in the absence of primary antibody. Primary murine monoclonal antibodies against 
a-SMA were obtained from Sigma and 3G5 antibodies (human monoclonal antibodies 
against CD44v3) from R&D Systems
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5.4 Results
CVCs showed characteristic stellate morphology, formed hills and valleys, and
developed calcifying nodules (Figure 5.1 A, B) over a period of 10 to 20 days. Cells 
expressed a-SMA extensively, and were also positive for 3G5, as previously described 
[57] (Figure 5.2 and 5.3A). Calcified nodules spontaneously fluoresced in the absence of 
antibody staining, as seen in control conditions (Figure 5.3A), but cells did not CVCs 
spontaneously calcified when cultured in basic growth medium, and addition of BMP7 at 
1.0 and 10 ng/ml significandy reduced the amount of calcification seen over 20 days but 
Vehicle and BMP7 at 0.1 ng/ml did not (Figure 5.4). The extent of reduction of 
calcification did not appear to vary with different effective doses of BMP7, suggesting an 
all-or-nothing effect over this range of doses, although further dose titration between 
these effective doses would be needed to demonstrate this. When grown in medium 
supplemented with lOmM (3GP, there was greater total calcification by CVCs (Figure 
5.5). BMP7 at 0.1,1.0 and 10 ng/ml significantly reduced this, although not to levels seen 
in the absence of {3GP. Again, vehicle alone had no effect.
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Figure 5.1 Calcification associated with calcifying vascular cells. Nodules o f calcification are
shown on layers o f  cells arranged in a *11111 and valley’ pattem( phase-contrast, unstained (A), and stained 
with Alizarin Red-S (B)). Bars = 150 pm
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Figure 5.2 Calcifying vascular cells stain with antibodies for a-Smooth muscle actin. A
nodule is showing auto-fluorescence to the left o f  panel (a, x40, bar = 50pm), with adherent smooth muscle 
cells to the right. Staining clearly defines myofibrils within the cells (b, x400, bar =  5pm).
Figure 5.3 Calcifying vascular cells stain with the antibody 3G5. (a) Stained cells (x40, bar
50|xm); (b) control cells showing auto-fluorescence o f  nodules but not cells (xlO, Bar = 200pna).
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Figure 5.4 Calcification by calcifying vascular cells in response to B M P 7  administration. (A)
Cells cultured under basal conditions. (B) Medium supplemented with P-glycerophosphate to promote 
calcification. * p <0.05 vs control.
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5.5 Discussion
These experiments demonstrate that BMP-7 reduces calcification by CVCs, both in the
presence and absence of an organic phosphate source, (3GP. This finding supports the 
hypothesis that the benefits of BMP-7 on vascular calcification seen in vivo are mediated, 
at least in part, by direct effects on the vasculature, in addition to beneficial effects 
mediated through amelioration of renal bone disease and extracellular calcium and 
phosphate ion concentration. Since CVCs are in essence VSMCs selected over a number 
of passages in culture for their propensity to calcify spontaneously, they are likely to 
represent such cells at an advanced stage of osteoblastic transdifferentiation. Thus it is 
unlikely that BMP-7 is reducing calcification by preventing the transdifferentiation 
process itself, but rather is modifying the calcifying behaviour of differentiated cells. This 
may have importance when translating these findings to an in vivo or clinical setting, since 
it suggests that BMP7 may have the potential to ameliorate vascular calcification in 
settings where VC is already established, as well as preventing its initial emergence. The 
fact that the beneficial effects of BMP7 were also seen in the presence of concentrations
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of (3GP in the media selected to maximise calcification is also important, since phosphate 
is a strong promoter of VC in the clinical environment.
This effect of BMP7 on cells of vascular origin represents a novel effect of 
BMP7. While BMP7 expression in cardiovascular tissues is extensive in embryonic 
development, as discussed in section 2.2.4, its precise role is unclear, and no role is 
defined in the adult This data supports the concept that BMP7 may act to sustain 
normal VSMC phenotype, although the mechanisms underlying this need further 
elucidation. It also suggests the possibility that BMP7 may benefit VC where it occurs in 
the absence of CKD and attendant renal osteodystrophy, where abnormalities of 
osteoblast biology are not necessarily relevant to the aetiology of VC.
One factor not investigated in these studies is the amount of TGFB expressed 
and secreted by these calcifying cells. This may influence the results of such experiments 
in a number of ways, particularly if there is variation between cell isolates. Firstly, as 
discussed in section 2, TGFB has been shown to promote VC by CVC [57]. Second, 
TGFB has been shown to promote changes in gene expression in VSMC in culture that 
are consistent with emergence of an osteoblastic phenotype [67], and thirdly in this latter 
study, it was shown that BMP7 is able to counteract these changes induced by TGFB. 
Thus the amount of calcification observed and the effect of a given dose of BMP7 in 
preventing it is likely to depend on the amount of TGFB expression by the cells under 
study. This will need further clarification in future studies, in parallel with studies to 
clarify the interaction between BMP7 and VSMCs and related cells such as CVCs as a 
whole.
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Section 6
Conclusions and future directions
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6.1 Conclusions
Recently there has been a significant increase in clinical and academic interest in vascular
calcification (VC), following the publication of studies linking this phenomenon to 
adverse cardiovascular outcomes [13-16, 34]. Such increased interest has been particularly 
apparent in relation to renal disease, where VC is a particularly striking clinical problem 
in patients with chronic and end-stage renal failure [17], and where cardiovascular 
morbidity and mortality are extremely high [11].
Accordingly, VC is considered to be an active process with strong parallels to 
endochondral bone mineralization [12], orchestrated by a population of cells in the vessel 
wall expressing an osteoblastic phenotype. These cells appear to be derived from vascular 
smooth muscle cells by a process of transdifferentiation. In the particular setting of renal 
failure, but not necessarily elsewhere, VC also seems to be linked to abnormalities of 
bone mineral metabolism inherent in renal osteodystrophy (ROD) [12, 17], particularly 
hyperphosphataemia [4]. Nevertheless, despite this increase in understanding, the
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mechanisms underlying the pathophysiology of VC remain unclear. Thus VC remains a 
considerable challenge to clinicians, since cardiovascular mortality is persistently high 
despite improvements in the management of many aspects of CRF and ESRD, and the 
life-expectancy of ESRD patients remains shortened. Indeed, evidence suggests that VC 
may in part be an iatrogenic problem in this setting, since severity of VC has been 
correlated radiologically to the use of several common therapies used in the treatment of 
ROD such as calcium-containing phosphate binders and Vitamin D analogues [17, 19]. 
In support of this, recent studies have suggested that Sevelamer, a newer phosphate 
binder that does not contain calcium, may prevent progression of VC in patients in 
established ESRF over six to twelve months follow-up [128,129]; however this data has 
not as yet been linked to improved survival, and it is important to note that the use of 
Sevelamer has been associated with a failure of progression of VC rather than a 
regression of established disease.
At the same time as awareness of the clinical significance of VC has grown, CRF has 
become characterised as a state of relative deficiency of the growth factor Bone 
Morphogenetic Protein 7 (BMP7) [130]. Reduced expression of BMP7 occurs soon after 
renal injury [75, 76], and administration of exogenous BMP7 is beneficial to several 
aspects of renal failure in a number of animal models, including progressive interstitial 
fibrosis [91], diabetic nephropathy [92] and renal osteodystrophy [94, 95] . This concept 
may also be relevant to the pathophysiology and treatment of VC.
It was hypothesised that VC may also be a manifestation of relative BMP7 deficiency in 
CRF, and that administration of exogenous BMP7 might therefore improve or prevent it. 
Although the role of BMP7 in the adult cardiovascular system is not understood, in vitro 
data suggests BMP7 may prevent changes in gene expression consistent with osteoblastic
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transdifferentiation seen in VSMCs following exposure to TGFB [67]. Thus the relative 
absence of BMP7 in CRF may facilitate these changes, and its replacement should 
reverse them. In addition, the beneficial effects of BMP7 on bone biology demonstrated 
in the context of ROD would also be expected to benefit VC by normalising calcium and 
phosphate ion metabolism and thereby removing an important stimulus for VC. Such a 
hypothesis, if confirmed, would strongly support a clinical role for BMP7-based therapy.
In contrast, it was also possible to hypothesise that exogenous BMP7 might have 
precisely the opposite effect and exacerbate VC, by promoting the osteoblastic 
transdifferentiation of VSMCs that seems to be central to the pathogenesis of VC. This 
argument is supported by the observation of BMP2 expression in the context of VC that 
is proposed to be an initiating event [39], and also the role of BMP7 in promoting 
maturation and function of osteoblasts in normal endochondral bone [80, 125]. If this 
were the case, the adverse impact of worsened VC on cardiovascular mortality could 
outweigh the benefits of exogenous BMP7 administration on other aspects of CRF, and 
significantly limit its therapeutic potential. The studies in this thesis were designed to 
evaluate the relative merits of these two paradoxical, though not necessarily mutually 
exclusive, hypotheses.
In section 3, Idlr1' mice were used as a model of vascular calcification. While this is a 
complex model of atherosclerosis onto which uraemia was superimposed, its elements 
are directly comparable to the complex clinical setting for many patients with chronic 
renal failure, with dyslipidaemia and mild glucose intolerance included. Rodent species 
are generally resistant to VC, but arterial mineralization occurs spontaneously in these 
mutant animals, albeit at low levels. The study successfully demonstrated that
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superimposition of uraemia worsened VC on histological grounds, and that 
administration of BMP7 prevented its occurrence almost entirely. We can conclude that 
BMP7 prevents VC in the setting of CRF. In addition, the data on osteocalcin expression 
are consistent with the conclusion that BMP7 treatment prevents the emergence of a cell 
in the vessel wall expressing an osteoblastic phenotype. Nevertheless, this study leaves 
open the question as to whether these beneficial effects of BMP7 are attributable to 
direct effects on the vasculature , indirect effects on bone and mineral metabolism or a 
combination of the two.
In section 4, further studies in the Idlr1' model of VC in CKD used a chemical assay of 
total aortic calcium content to confirm the histological finding that BMP7 administration 
reduces VC. In addition, bone histomorphometry clearly demonstrates that uraemic Idlr1' 
mice develop an adynamic bone disease. This was an unexpected finding, since uraemia 
is usually associated with a high bone turnover state, and these mice were not receiving 
treatment that could be expected to induce an adynamic picture. On the other hand, it is 
possible to hypothesise that the reduction of BMP7 expression that occurs soon after 
renal injury may lead to reduced bone anabolism at a stage of CKD when mineral ion 
homeostasis and vitamin D concentrations may still be relatively normal. This reduction 
in anabolism may then in turn be a stimulus for the initiation of hyperparathyroidism and 
Osteitis Fibrosa, since PTH is able to promote osteoblastic maturation, albeit aberrantly 
[74, 131]. Clearly this hypothesis is based on animal data and requires confirmation in 
humans
In addition, the low bone turnover state seen in this model may conceivably be attributed 
to the dyslipidaemia that characterises the Idlr1' mutation. Previous clinical observations 
have linked vascular calcification and osteoporosis (another low-tumover bone disease)
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[132, 133], and in vitro data attributes to certain lipid moieties both the ability to increase 
calcification by vascular cells and to impair maturation of osteoblastic cells [134]. In 
addition, adynamic bone disease is more commonly seen in diabetic patients, and the 
mild glucose intolerance of these animals may thus be contributory. Nevertheless, while 
the bone findings are somewhat unexpected, they still fall within the documented clinical 
spectrum of ROD, and are expected to contribute to the pathogenesis of VC through 
elevations in plasma calcium and phosphate ion concentrations. While elevations in the 
concentrations of these ions may occur through release from bone by increased 
resorption in high turnover forms of ROD, similar abnormalities may occur in adynamic 
states through different mechanisms. ABD is associated with a reduced Rapidly 
Diffusible Ion Pool in proportion to a reduced mineralising area, and this reduces the 
capacity to buffer extracellular calcium and phosphate ions. Thus, exaggerated 
fluctuations of these ions may occur, particularly post-prandially, and this may be a 
potent stimulus to VC. The histomorphometry data in this study clearly show 
normalisation of bone parameters in the BMP7-treated uraemic animals, in parallel with 
improvement in vascular calcification, which agrees with data from a study in a specific 
model of ABD [74] which also showed normalisation of bone histomorphometry 
parameters in response to BMP7 treatment. It also complements a study of the effects 
of BMP7 on a high turnover model of ROD [94]. From the point of view of the 
hypotheses relevant to this thesis, it is possible to conclude that BMP7 administration 
causes improvements in VC in parallel with changes in bone physiology likely to reduce 
factors known to promote its pathogenesis.
The studies described in section 5 address the question of whether or not BMP7 has 
direct effects of cells of vascular origin that might contribute to the reduction in VC seen 
in the previous experiments. Calcifying Vascular Cells (CVCs) are well established as cells
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that have all the characteristics of smooth muscle cells but also display an osteoblastic 
phenotype and spontaneously mineralise their extracellular matrix. Our studies 
demonstrate that BMP7 is able to reduce calcification by CVCs under basal culture 
conditions and also when the growth medium is supplemented with (3-glycerophosphate 
to maximise mineralization. It should also be noted that this represents a different 
therapeutic strategy to the previous studies, in that here the cells being treated are already 
established in their osteoblastic phenotype, whereas the timing of BMP7 administration 
in the animal studies exposes vascular tissues to BMP7 as soon as uraemia is established 
and before significant transdifferentiation could be expected to occur. In addition, the 
cell model does not include a uraemic component, and thus suggests that BMP7 may 
benefit VC in other situations than CRF.
In summary, the conclusion of this thesis is that that exogenous BMP7 administration 
reduces or prevents vascular calcification in a murine model of CRF, dyslipidaemia and 
atherosclerosis, and that this benefit is likely to reflect direct effects on vascu lar tissues as 
well as indirect effects on mineral metabolism mediated through normalisation of bone 
structure and function.
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6.2 Future directions
I t  is clear that a number of questions arise from the results of these studies, some 
specific to these experiments and some more general.
Firstly, data in section 5 demonstrate an interaction between BMP7 and CVCs, which are 
cells of vascular origin with characteristics of VSMCs but which also express an 
osteoblastic phenotype. While the role of BMP7 in normal osteoblast biology is 
established, a role in normal VSMC biology, if any, is undefined. Thus the mechanisms 
underlying the observed effects on extracellular mineralization are unclear at present, and 
are a key area for further investigation. There is evidence to suggest that BMP7 may 
interact with TGFB in an antagonistic way at the level of Smad signalling [130], and data 
discussed in the appendix also suggest that interactions with Wnt signalling channelled by 
LRP5 through (3-Catenin may be important. LRP5 is a member of the Low Density 
Lipoprotein Receptor family of cell surface receptors, and is essential for normal 
osteoblast function [135]. Single-nucleotide mutations in this gene have been linked to
striking bone mineral abnormalities in human disease [136-140]. Both activating and 
inactivating mutations are described, and are associated with extremely dense, 
mechanically strong bones [136-139] or juvenile osteoporosis respectively [140]. As 
demonstrated in the appendix, expression of LRP5 is increased in vascular tissues in both 
ldlr,~ and wild type animals fed the high cholesterol diet, and this protein may thus 
represent a link between VC and both the genetic mutation in our model and the general 
condition of dyslipidaemia and atherosclerosis.
A further point for future exploration concerning LRP expression and the use of BMP7 
as a therapeutic agent concerns the potential impact of another member of this family, 
LRP1, on the pharmacokinetics of BMP7. BMP7 is bound to the plasma protein a2 
macroglobulin in the circulation, and is removed in the liver by combining with LRP1, 
which is expressed on the surface of hepatocytes. As outlined in the Appendix, 
expression of LRPs may be altered in the response to high cholesterol diet, in the context 
of the Idlf1' genotype and other genetic models of dyslipidaemia [122]. In particular, there 
is evidence that liver expression of LRP1 may be increased, raising the possibility that the 
half-life of BMP7 in the circulation may be reduced in hyperlipidaemic states. Clearly, 
this may be an important consideration if BMP7 therapy is developed into the clinical 
arena, and pharmacodynamic studies will need to be performed.
In addition, recent evidence suggests that modulation of extracellular matrix 
glycosaminoglycans such as hyaluronan may be relevant to the mechanism of interaction 
of BMP7 with VSMCs or CVCs. It has been shown that BMP7 may modulate haluronan 
synthesis in renal mesangial cells and modify cell behaviour by doing so [141]. 
Hyaluronans bind to and signal within cells through the cell surface protein CD44. The 
fact that mesangial cells may be regarded as modified smooth muscle cells suggests that
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similar effects may occur in VSMCs, and the fact that VSMCs increase expression of 
CD44 when adopting the osteoblastic phenotype, as evidenced by the staining of CVCs 
with the anti-CD44 antibody 3G5 (Figure 5.3), suggests that altered interactions between 
these cells and hyaluronan in the extracellular matrix may be important to their 
emergence as cells with calcifying potential.
Finally, in general terms it is clear that demonstrable efficacy of exogenous BMP7 
administration in improving so many aspects of renal failure in such a wide variety of 
models offers the exiting prospect that mortality associated with chronic kidney disease 
and end-stage renal failure and its consequences may be preventable or treatable for 
many patients in the future. BMP7 has already been used in clinical orthopaedic studies 
looking at its role in promoting fracture healing [142], and synthetic and modified BMP7 
analogues are under investigation that may be suitable for evaluation in human studies 
[143]. It may even be the case that BMP7 has a role to play in treating vascular 
calcification outside the context of renal failure, with potential benefits to cardiovascular 
morbidity and mortality in the population at large.
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Appendix A
The potential role o f low density lipoprotein receptor-related 
protein 5 (LRP5) in the aetiology of vascular calcification in 
the ldlr'/m mouse
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A.1 Aim
O ne question that arises from the studies described in the foregoing sections is whether
or not the Idlr1' genotype can itself directly affect bone and vascular mineralisation. The 
LDLR is a member of a larger family of structurally similar cell surface receptors, and 
there is evidence to suggest that expression of other members of the LDLR family may 
change in response to the Idlr1' lesion. One member of this family, low-density 
lipoprotein receptor related-protein 5 (LRP5) has recently been shown to play a role in 
determining bone density, and so changes in LRP5 expression may be particularly 
relevant to the emergence of abnormal bone and vascular mineralisation patterns in this 
model.
The preliminary studies described in this section were designed to provide initial data to 
clarify this issue, by assaying levels of mRNA expression for LRP5 in Idlr1' and wild type 
(WT) mice, when fed either standard chow or the high fat, high cholesterol diet 
previously discussed. The studies used Reverse Transcription Polymerase Chain Reaction
173
(RT-PCR) and Real-Time RT-PCR to quantify relative mRNA levels in a number of 
tissues from these animals. The preliminary nature of the data from these studies is 
emphasised, and explains their inclusion as an appendix rather than in the body of this 
thesis.
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A.2 Background and hypothesis
T he LDLR is a member of a family of structurally similar but functionally disparate cell
surface receptors that includes a number of LDLR-related proteins, or LRPs [144]. In 
contrast to LDLR, which serves primarily as a receptor for low density lipoproteins, 
LRPs interact with a variety of extracellular ligands. The expression of a number of 
members of this family, including LRP1, have been shown to be increased in liver and 
other tissue of a number of models of hyperlipidaemia including Idlr1', under certain 
conditions [122]. This observation suggests the possibility that abnormal patterns of LRP 
expression may also occur in this genetic model of vascular calcification. One factor that 
may be particularly relevant to both bone and vascular calcification is LRP5. This protein 
acts as a co-receptor with members of the Frizzled family of receptors for the Wnt family 
of ligands [145], and may direct signalling related to these ligands through the canonical, 
(3-Catenin-dependant intracellular pathway. In addition, LRP5 is able to bind extracellular 
inhibitors of Wnt/Frizzled, including members of the Dickkopf (Dkk) family of proteins
LRP5 has emerged as an important factor in normal bone mineralisation, and is 
expressed by osteoblasts [147]. Functional activation of LRP5 due to single point 
mutation has been associated with abnormally dense, but structurally normal bones in 
two large human kindreds [137, 139]]. Individuals with the activating mutation have 
extremely high bone density on dual energy x-ray absorbtiometry (DEXA) scanning that 
is two standard deviations or more beyond the population mean, giving Z scores at a 
single site of 2 or more, and combined Z scores at two sites of 4 or more. While life 
expectancy is normal and there is no significant morbidity associated with the lesion, it is 
interesting to note that traumatic fractures are virtually unheard of throughout these 
extensive kindreds. In addition, this phenotype has been successfully reproduced in a 
transgenic animal model [136]. Other studies supporting a key role of LRP5 in 
determining bone mineral density and strength is the description of an inactivating 
mutation of this same gene associated with a syndrome of juvenile osteoporosis, 
Osteoporosis Pseudoglioma syndrome (OPPS) [140], and the association of 
polymorphisms of LRP5 with bone density in Caucasian and Japanese populations [138, 
148].
Relevant to the studies described in this thesis, it is further possible to hypothesise a link 
between LRP5 function and BMP7 signalling at a cellular level. Cooperativity between 
Wnt and BMP signalling pathways has been shown in at least in the setting of 
embryological development [149]. In this example, both pathways may simultaneously 
act on the same target gene, as well as influencing the expression levels of moieties in the 
other pathway. Nevertheless, there is no direct evidence at present for interaction 
between BMP7 and LRP5 signalling specifically.
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Thus functional changes attributable to changes in expression of LRP5 may be relevant 
to the abnormal calcification seen in the Idlr 7' phenotype, both in terms of normal bone 
mineralisation and pathological VC, and further, may influence the therapeutic response 
to BMP7 in this setting. It was hypothesised that LRP5 expression would be increased in 
vascular tissues of Idlr 7‘ mice, and influenced by the hyperlipidaemia associated with the 
high cholesterol, high fat diet used in the studies described in sections 4 and 5.
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A.3 M ethods
A.3.1 Animals and diets
Experiments were conducted according to the guidelines of the Washington University
Animal Care committee (http://medicine.wustl.edu/~acu). Idlr1' mice were fed a chow 
diet until 10 weeks of age, then either continued to receive chow or were fed high fat 
high cholesterol diet as used in previous studies for two weeks. Ten week old wild type 
(WT) C57/B16 mice purchased from Harlan Teklad were fed either standard laboratory 
chow or the same high fat, high cholesterol diet for two weeks. All animals had access to 
water ad libitum. After two weeks on their respective diets, animals were sacrificed under 
anaesthesia (intraperitoneal xylazine 13mg/kg and ketamine 87mg/kg), and their internal 
organs rapidly dissected, then flash-frozen in dry ice /  ethanol slurry. Samples were then 
immediately processed for mRNA extraction or stored at — 80 °C.
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A.3.2 Messenger RNA extraction
RNA extraction was performed using ‘RNAqueous™-4PCR’ Kit (Ambion, Austin, TX)
according to manufacturer’s instructions. Briefly, total RNA was extracted from tissue 
samples by homogenisation in a buffer containing guanidinium thiocyanate, a denaturant 
that lyses cell membranes and inactivates cellular ribonucleases. The lysate is then mixed 
with 64% ethanol solution, and applied to a silica-based filter that selectively and 
quantitatively binds messenger RNA (mRNA) and larger ribosomal RNA but not 
transfer RNA (tRNA) or smaller ribosomal RNAs. The filter is washed to remove 
residual DNA and protein contaminants, and mRNA eluted from the filter in nuclease- 
ftee water containing 0.1 mM EDTA to chelate heavy metal ions. Trace amounts of 
DNA contamination were removed by DNase I treatment of the eluate, followed by 
DNase inactivation. Quantification of the product was confirmed by absorbtiometry at 
260nm.
A.3.3 RT-PCR
Reverse transcription to generate cDNA from the RNA isolated above used the
Onestep RT-PCR kit (Qiagen, Valencia, CA), according to manufacturer’s instructions. 
Expression of LRP5 was compared with the housekeeping gene GAPDH using the 
primers shown in table 7.1. LRP5 primers were as described [150], and GAPDH derived 
from Genbank sequences. Reaction mixtures variously included 20 - 100 ng template, 
based on eluate concentrations of mRNA derived by absorbtiometry, above. The
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following cycles were used: Step One: 1 cycle of 30 minutes at 50 °C; Step Two: 1 cycle 
of 15 minutes at 95 °C; Step Three: 35 cycles of 1 minute at 94 °C, 1 minute at 54 °C, 
and 1 minute at 72 °C; Step Four: 1 cycle of 10 minutes at 72 °C; then hold at 4 °C.
Primer Sequence
(5’-3>)
Product
size
Lrp5 Sense
Antisense
AAG CTC AGC TTC ATC CAC CG 
TCC CGT CTA TGT TGA TCA CCT CG
900 bp
Gapdh Sense
Antisense
AAC GGA TTT GGC CGT ATT GGC CGC 
CCT GCA TCT GCC CAT TTG ATG TTG
300 bp
Table A.1 Characteristics of primers for LRP5 and GAPDH used for Reverse transcription 
polymerase chain reaction (RT-PCR). See text for full explanation.
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A.3.4 Real Time RT-PCR
T o  quantify RNA expression change in response to fat diet in aortic tissues, real time
RT-PCR was performed using the reaction conditions given above, using 40 cycles of 
step 3. SYBR ® green, a fluorescent dye that binds selectively to double-stranded DNA, 
was added to the reaction mixture in place of an equal volume of dH20  to enable 
identification of the amplification product. Fluorescence was detected with an ABI prism 
5700 sequence detection system (PE Biosystems). The threshold cycle (Cp), which is 
defined as the cycle number at which the amount of amplified product reaches a fixed 
threshold, was obtained for LRP5 and GAPDH as a reference gene. The expression 
ratio of mRNA under various experimental conditions was calculated from the general 
formula:
Expression ratio = ER = 2~AACt.
To estimate LRP5 ER in relation to diet for the two genotypes, the following equations 
were used to calculate AACt:
1. AACjlqlr — ACX(LRP5 ldlrpj,) -ACt(LRP5 ldlroiow)»
2. AACpwr = ACt(LRP5 wmt) -ACt(LRP5 wTChow)
To estimate LRP5 ER in relation to genotype for the two diets, the following equations 
were used:
and ACt(LRP5fJ  = CT(LRP5FJ  - CT(GAPDHFat).
3. AACXChow — ACX(LRP5 wtoiow) -ACX(LRP5 ldlroiow)*
4. AACpp,, — ACX(LRP5 vtTPai) -ACX(LRP5 LDLRFat)»
where ACX(LRP5 xx>LRFat) — CX(LRP5 l d l r f ^  ~ CX(GAPDH l d l r f « )
ACr(LRP5 LDLRChow) = Cp(LRP5 ldlrchow) * Cr(GAPDH ldlroiow)
AGr(LRP5 wrFat) — Cr(LRP5 ^mt) * (^(GAPDH T^Fat) 
and ACX(LRP5 wTChow) = (^(LRPS wtqiow) " Cp(GAPDH wtoiow)
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The Cx value for each genotype and diet was measured in triplicate, and the mean CT 
used for analysis.
Primers were modified to generate smaller products for LRP5 and GAPDH, in the 
optimal size-range for real time RT-PCR of 50-150 bp. Reaction conditions were 
optimised accordingly.
Primer Sequence 
(S’ -3 0
Product
size
LRP5 Sense
Antisense
CTA GAT GGG AGA GAT CGG CA 
TCC CGT CTA TGT TGA TCA CCT CG
138 bp
Gapdh Sense
Antisense
AAC GGA TTT GGC CGT ATT GGC CGC 
GTG CCG TTG AAT TTG CCG TGA GTG
150 bp
Table A.2 Characteristics of primers for LRP5 and GAPDH used for Real Time RT-PCR. See text 
for full explanation.
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Aortic samples from two Idlr 7 animals fed chow, three Idlr 7' animals fed high fat, and 
three WT animals fed each diet were analysed for LRP5 and GAPDH (11 animals in all). 
Each sample was analysed in triplicate. For each sample, expression of LRP5 was 
normalised to the expression of GAPDH by comparing the mean difference in number 
of cycles required to reach a preset amplification threshold for each product The mean 
of these normalised values was derived for each of the four animal groups defined by 
genetic lesion and diet The normalised values for fat-fed animals were then expressed as 
a ratio relative to chow-fed animals for each genotype.
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A.4 R esults
RT-PCR was used to define the expression of LRP5 if any in tissues of Idlr1' mice in
relation to high fat diet or feeding with regular chow. Widespread expression of LRP5 
was confirmed in a number or organs of animals fed high fat diets, including spleen, 
kidney liver and aorta (Figure A.1). Aortic expression of LRP5 was detected in none of 
the chow-fed animals, but all (3/3) of the animals on the high fat diet. Expression was 
not detected in lung, liver or colon, even with higher amounts of mRNA template and 
more cycles, irrespective of diet. Tissue assays by RT-PCR were not performed on 
sample from WT animals.
Further quantification of these findings was performed in aortic tissues by Real time 
RTPCR. This showed increased expression of LRP5 in aorta from both Idlr '1' and WT 
animals when fed the high fat diet (Figure A.2A). In Idlr1' the increase was estimated to 
be 1600-fold, and in WT animals 200-300 fold. While the standard deviations of these 
estimates are large, reflecting sample size, they do not span zero, and suggest that an up-
regulation is occurring. The high ratio for Idlr1' tissue may in part reflect the low levels 
seen in chow-fed animals. When comparing the effect of genotype on LRP5 expression 
under each dietary condition, WT animals surprisingly appeared to have higher levels of 
expression with both high fat and chow. However, the ratios are not large, and standard 
deviations overlap zero, such that confidence in these findings must be low.
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Chow 1 Chow 2 Chow 3
Fat 1 Fat 2 Fat 3
Figure A.1 Representative RT-PCR gels showing LRP5 mRNA expression in ld lr^ ' mice. Bands are seen 
at 900bp in liver and kidney o f one chow fed animal, and in liver, spleen and aorta variously in fat-fed animals. Aortic 
expression is seen in all three o f these animals. All lanes containing template demonstrated bands for GAPDH (Not 
shown) I i, liver; Sp, spleen; Ki, kidney; Ao, aorta; Co, colon; He, heart; Lu, lung; Bl, blank.
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Figure A.2 Quantitative estimates of increase in LRP5 expression in Aortic tissue. A. Comparison 
between Fat-fed and chow fed animals in each genotype. B.Comparison between Wild type and Idlr^'mice 
with diet Each data point expressed as mean ±  SD, n=3
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A.5 Discussion
Although preliminary, the data presented in this section demonstrate firstly that LRP5
expression is relatively easy to detect by RT-PCR in certain tissues from ldlrh animals, in 
particular liver and spleen. Aortic expression was more easily detectable in animals fed 
the high fat diet compared to those fed chow, suggesting increased LRP5 expression in 
response to this dietary change. Secondly, quantitative real-time RTPCR data from aortic 
tissue confirm increased LRP5 expression in response to high fat diets, both in Idlr1' and 
WT animals. Such a change suggests a possible mechanism by which dyslipidaemia may 
contribute to vascular calcification, given the emerging importance of a cell expressing an 
osteoblastic phenotype in the vasculature in the context of VC, and the requirement for 
LRP5 expression in normal osteoblast function. Further, the links between Wnt and 
BMP signalling pathways suggests that LRP5 expression may be relevant both to the 
manifestation of BMP7 deficiency in the context of CRF and to the response to therapy. 
It is known that cooperativity exists between Wnt and TGFfi superfamily signalling in 
models of renal fibrosis, through augmentation of the nuclear effects of co-Smad4.
Changes in Wnt signalling mediated by changes in LRP5 expression would be expected 
to exaggerate any imbalance between TGF6 and BMP7 in this setting, and equally may 
augment the biological response to BMP7 administration for similar reasons.
While these data are preliminary in nature, and care needs to be taken in drawing 
conclusions, it seems reasonable to conclude that LRP5 expression occurs in aortic 
tissues and that diet may influence the regulation of this, and as such control of LRP5 
expression and function seems to be an area deserving further investigation
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